<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US7297761 - Pharmaceutical compositions containing exendins - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Pharmaceutical compositions containing exendins"><meta name="DC.contributor" content="Nigel Robert Arnold Beeley" scheme="inventor"><meta name="DC.contributor" content="Kathryn S. Prickett" scheme="inventor"><meta name="DC.contributor" content="Sunil Bhavsar" scheme="inventor"><meta name="DC.contributor" content="Andrew Young" scheme="inventor"><meta name="DC.contributor" content="Bronislava Gedulin" scheme="inventor"><meta name="DC.contributor" content="Amylin Pharmaceuticals, Inc." scheme="assignee"><meta name="DC.date" content="2004-7-19" scheme="dateSubmitted"><meta name="DC.description" content="Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed."><meta name="DC.date" content="2007-11-20" scheme="issued"><meta name="DC.relation" content="AU:3173297" scheme="references"><meta name="DC.relation" content="US:5118666" scheme="references"><meta name="DC.relation" content="US:5120712" scheme="references"><meta name="DC.relation" content="US:5187154" scheme="references"><meta name="DC.relation" content="US:5264372" scheme="references"><meta name="DC.relation" content="US:5424286" scheme="references"><meta name="DC.relation" content="US:5512549" scheme="references"><meta name="DC.relation" content="US:5545618" scheme="references"><meta name="DC.relation" content="US:5574008" scheme="references"><meta name="DC.relation" content="US:5686511" scheme="references"><meta name="DC.relation" content="US:6191102" scheme="references"><meta name="DC.relation" content="US:6858576" scheme="references"><meta name="DC.relation" content="US:6902744" scheme="references"><meta name="DC.relation" content="US:6924264" scheme="references"><meta name="DC.relation" content="WO:1990011296:A1" scheme="references"><meta name="DC.relation" content="WO:1991011457:A1" scheme="references"><meta name="DC.relation" content="WO:1993018786:A1" scheme="references"><meta name="DC.relation" content="WO:1993025579:A1" scheme="references"><meta name="DC.relation" content="WO:1995007098:A1" scheme="references"><meta name="DC.relation" content="WO:1996006626:A1" scheme="references"><meta name="DC.relation" content="WO:1998005351:A1" scheme="references"><meta name="DC.relation" content="WO:1998019698:A1" scheme="references"><meta name="DC.relation" content="WO:1998030231:A1" scheme="references"><meta name="DC.relation" content="WO:1999007404:A1" scheme="references"><meta name="citation_reference" content="Adelhorst, K., et al, &quot;Structure-activity studies of glucagon-like peptide-1 (GLP-1),&quot; J. Bio Chem 269(9):6275-8 (1994)."><meta name="citation_reference" content="Bartlett, et al, &quot;Inhibition of Chymotrypsin by Phosphonate and Phosphonamidate Peptide Analogs,&quot; Bioorg. Chem. 14:356-377 (1986)."><meta name="citation_reference" content="Bayer et al., &quot;Advances in Poison Management,&quot; Clin. Chem., 42(8)(B):1361-66 (1996)."><meta name="citation_reference" content="Bhavsar, &quot;Inhibition of gastric emptying and of food intake appear to be independently controlled in rodents,&quot; Soc. Neurosci. Abst. 21:460 (188.8)(1995)."><meta name="citation_reference" content="Buffer solution (updated 2007) Wikipedia, &quot;Commone buffer compounds used in biology&quot;, http://en.wikipedia.org./□□wiki/Buffer&lt;SUB&gt;-&lt;/SUB&gt;solution, p. 1."><meta name="citation_reference" content="Chantry et al. (1991) Cross-reactivity of amylin with calcitonin-gene-related peptide binding sites in rat liver and skeletal muscle membranes. Biochem. J. vol. 277 (Pt 1), pp. 139-143."><meta name="citation_reference" content="Cohen, et al, The Pico Tag Method; A Manual of Advanced Techniques for Amino Acid Analysis, pp. 11-52, Millipore Corporation (1989)."><meta name="citation_reference" content="Cohen, S.A., Meys, M., and Tarrin, T.L. (1989), The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis, pp. 11-52, Millipore Corporation, Milford, MA)."><meta name="citation_reference" content="D&#39;Alessio et al. &quot;Elimination of the Action of glucagon-like Peptide 1 Causes an Impairment of glucose tolerance after Nutrient Ingestion by Healthy Baboons,&quot; J. Clin. Invest., 97:133-38, 1996."><meta name="citation_reference" content="D&#39;Alessio et al., &quot;Glucagon-like Peptide 1 Enhances Glucose Tolerance Both by Stimulation of Insulin Release and by Increasing Insulin-independent Glucose Disposal,&quot; J. Clin. Invest., 93:2263-66 (1994)."><meta name="citation_reference" content="Daniel et al. &quot;Use of Glucagon in the Treatment of Acute Diverticulitis,&quot; Br. Med. J., 3:720, 1974."><meta name="citation_reference" content="Dhillo et al. (2003) Paraventricular nucleus administration of calcitonin gene-related peptide inhibits food intake and stimulates the hypothalamo-pituitary-adrenal axis. Endocrinology. vol. 144, No. 4, pp. 1420-1425."><meta name="citation_reference" content="Eissele et al. &quot;Rat Gastric somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-Like Peptide-1 (GLP-1) Amide,&quot; Life Sci., 55:629-34, 1994."><meta name="citation_reference" content="Eng et al. &quot;Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from Heloderma suspectum Venom&quot;, J. Biol. Chem., 267:7402-05, 1992."><meta name="citation_reference" content="Eng et al. &quot;Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated from Heloderma horridum Venom,&quot; J. Biol. Chem., 265:20259-62, 1990."><meta name="citation_reference" content="Fehmann et al. &quot;Stable Expression of the Rat GLP-1 Receptor in CHO Cells: Activation and Binding Characteristics Utilizing GLP-I(7-36)-Amide, Oxyntomodulin, Exendin-4, and Exendin(9-39),&quot; Peptides 15 (3): 453-6, 1994."><meta name="citation_reference" content="Fehmann et al. &quot;Stable Expression of the Rat GLP-I Receptor in CHO Cells: Activation and Binding Characteristics Utilizing GLP-I(7-36)-Amide, Oxyntomodulin, Exendin-4, and Exendin(9-39),&quot; Peptides 15 (3): 453-6, 1994."><meta name="citation_reference" content="Ferguson et al. &quot;Cell-Surface Anchoring of Proteins Via Glycosylphosphatidylinositol Structures&quot;, Annu. Rev. Biochem. 57:285-320 (1988)."><meta name="citation_reference" content="Ferguson et al. &quot;Cell-Surface Anchoring of Proteins Via Glycosylphosphatidylinositol Structures&quot;, Annu. Rev. Biochem. 57:285-320, 1988."><meta name="citation_reference" content="Gedulin et al. &quot;Comparison of Effects of Amylin, Glucagon-like Peptide-1 and Exendin-4 to Inhibit Pentagastrin-Stimulated Gastric Acid Secretion,&quot; Diabetologia, 40 (Suppl. 1):A300 (Abstract 1181) (1997) 8:228, 1979."><meta name="citation_reference" content="GenBank Accession No. CAA24759, Feb. 9, 1999."><meta name="citation_reference" content="Glauser et al. &quot;Intravenous glucagon in the Management of Esophageal Food Obstruction&quot;, J. Am. Coll. Emergency Physns, 8:228, 1979."><meta name="citation_reference" content="Goke et al. &quot;Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting beta-Cells&quot;, J. Biol. Chem., 268:19650-55, 1993."><meta name="citation_reference" content="Goke et al. &quot;Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting -Cells&quot;, J. Biol. Chem., 268:19650-55, 1993."><meta name="citation_reference" content="Goldstone et al, FEBS Letters, vol. 415, pp. 134-138, 1997."><meta name="citation_reference" content="Holst, &quot;Glucagonlike Peptide-1: A Newly Discovered Gastrointestinal Hormone,&quot; Gastroenterology, 107:1848-55 (1994)."><meta name="citation_reference" content="Introduction to Cleavage Techniques, Applied Biosystems, Inc., 1990, pp. 6-12."><meta name="citation_reference" content="Kodama, J., et al, &quot;Effect of Captopril on Glucose Concentration Possible Role of Augmented Postprandial Forearm Blood Flow,&quot; Diabetes Care 13(11):1109-1111 (1990)."><meta name="citation_reference" content="Kolligs et al. &quot;Reduction of the Incretin effect in Rats by the Glucagon-Like Peptide 1 Receptor antagonist Exendin(9-39) Amide&quot;, Diabetes, 44:16-19, 1995."><meta name="citation_reference" content="Kolligs, et al, &quot;Reduction of the incretin effect in rats by the glucagon-like peptide-1 receptor antagonist exendin (9-39) amide,&quot; Diabetes 44:16-19 (1995)."><meta name="citation_reference" content="Lawler et al., &quot;Comparison of Effects of Amylin, Glucagon-like Peptide-1 (GLP-1) and Exendin-4 to Inhibit Pentagastrin-Stimulated Gastric Acid Secretion in Rats,&quot; Gastroenterology, 112(4):A194, (1997)."><meta name="citation_reference" content="Leibel, R.L., et al, &quot;Changes in Energy Expenditure Resulting from Altered Body Weight,&quot; New England Journal of Medicine 332(10):621-628 (1995)."><meta name="citation_reference" content="Lithell, et al, &quot;Insulin Sensitivity in Newly Detected Hypertensive Patients: Influence of Captopril and Other Antihypertensive Agents on Insulin Sensitivity and Related Biological Parameters,&quot; J. Cardiovasc. Pharmacol. 15 (Supp 5):S46-S52 (1990)."><meta name="citation_reference" content="Malhotra et al. &quot;Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini&quot;, Regulatory Peptides, 41:149-56, 1992."><meta name="citation_reference" content="Miholic et al., &quot;Glucagon-like Peptide-1 (GLP-1), Entleerung des Magenersatzes und das Dumpingsyndrom nach Gastrektomie,&quot; Chirurgishes Forum, 1991, pp. 429-432 (English abstract and International Search Report in which the article is referenced are attached)."><meta name="citation_reference" content="Montrose-Rafizadeh et al. &quot;Structure-function Analysis of Exendin-4 / GLP-1 Analogs&quot;, Diabetes, 45(Suppl. 2):152A, 1996."><meta name="citation_reference" content="Nauck et al., &quot;Effects of Subcutaneous Glucagon-like Peptide 1 (GLP-1 [7-36 Amide]) in Patients with Type 2-Diabetes,&quot; Diabetologia, Abstract A148, 38 Supp. 1:A39 (1995)."><meta name="citation_reference" content="Navarro, M. et al., &quot;Colocalization of Glucagon-Like Peptide-1 (GLP-1) Receptors, Glucose Transporter GLUT-2, and Glucokinase mRNAs in Rat Hypothalamic Cells: Evidence for a Role of GLP-1 Receptor Agonists as an Inhibitory Signal for Food and Water Intake,&quot; Journal of Neurochemistry, 67:1982-1991 (1996)."><meta name="citation_reference" content="O&#39;Halloran et al. &quot;Glucagon-like peptide-1 (7-36)-NH&lt;SUB&gt;2&lt;/SUB&gt;: a physiological inhibitor of gastric acid secretion in man,&quot; J Endocrinol 126 (1): 169-73, 1990."><meta name="citation_reference" content="O&#39;Halloran et al. &quot;Glucagon-like peptide-1 (7-36)-NH&lt;SUB&gt;2&lt;/SUB&gt;: a physiological inhibitor of gastric acid secretion in man,&quot; J. Endocrinol 126 (1): 169-73 (1990)."><meta name="citation_reference" content="Ørskov et al. &quot;Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable&quot;, Diabetes, 42:658-61 (1993)."><meta name="citation_reference" content="Orskov et al. &quot;Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable&quot;, Diabetes, 42:658-61, 1993."><meta name="citation_reference" content="Orskov et al., &quot;Is the Effect of Glucagon-like Peptide-1 on Gastric Emptying Centrally Mediated?&quot;, Diabetologia, Abstract A147, 38 Supp. 1:A39, (1995)."><meta name="citation_reference" content="Pelleymounter, et al, &quot;Effects of the obese Gene Product on Body Weight Regulation in ob/ob Mice,&quot; Science 269:540-543 (1995)."><meta name="citation_reference" content="Raufman et al. &quot;Exendin-3, a Novel Peptide from Heloderma horridum Venom, Interacts with Vasoactive Intestinal Peptide Receptors and a Newly Described Receptor on dispersed Acini from Guinea Pig Pancreas,&quot; J. Biol. Chem. 266:2897-902 (1991)."><meta name="citation_reference" content="Raufman et al. &quot;Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas&quot;, J. Biol. Chem. 267:21432-37 (1992)."><meta name="citation_reference" content="Raufman et al. &quot;Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas&quot;, J. Biol. Chem. 267:21432-37, 1992."><meta name="citation_reference" content="Ritzel et al., &quot;GLP-1 [7-36 Amide] Augments Bisphasic Insulin Secretion After Intravenous Glucose in Healthy Volunteers,&quot; Diabetologia, Abstract A145, 38 Supp. 1:A39, (1995)."><meta name="citation_reference" content="Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor 1989."><meta name="citation_reference" content="Scarpignato et al. &quot;Action of Caerulein on gastric emptying of the Conscious Rat&quot;, Arch. Int. Pharmacodyn. Ther. 246:286-94,1980."><meta name="citation_reference" content="Schepp et al. &quot;Exendin-4 and exendin-(9-39)NH&lt;SUB&gt;2&lt;/SUB&gt;: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH&lt;SUB&gt;2&lt;/SUB&gt;,&quot; Eur. J. Pharm. 269:183-91 (1994)."><meta name="citation_reference" content="Schepp, et al. &quot;Exendin-4 and exendin-(9-39)NH&lt;SUB&gt;2&lt;/SUB&gt;: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH&lt;SUB&gt;2&lt;/SUB&gt;,&quot; Eur. J. Pharm. 269:183-91, 1994."><meta name="citation_reference" content="Schjoldager et al. &quot;GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans,&quot; Dig Dis Sci 34 (5): 703-8 (1989)."><meta name="citation_reference" content="Singh et al. &quot;Use of &lt;SUP&gt;125&lt;/SUP&gt;1-[Y&lt;SUP&gt;39&lt;/SUP&gt;]exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig,&quot; Regul. Pept. 53:47-59 (1994)."><meta name="citation_reference" content="Singh et al. &quot;Use of &lt;SUP&gt;125&lt;/SUP&gt;I-[Y&lt;SUP&gt;39&lt;/SUP&gt;]exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig,&quot; Regul. Pept. 53:47-59 (1994)."><meta name="citation_reference" content="Stower et al. &quot;A trial of glucagon in the treatment of painful biliary tract disease,&quot; Br. J. Surg., 69:591-2, 1982."><meta name="citation_reference" content="Strandberg et al (Acta Radiologica, 1988, vol. 29, pp. 49-52)."><meta name="citation_reference" content="Thorens et al. &quot;Cloning and Functional Expression of the Human Islet GLP-1 Receptor,&quot; Diabetes 42 (11): 1678-82, 1993."><meta name="citation_reference" content="Thorens, &quot;Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1,&quot; Proc. Natl. Acad. Sci. USA 89:8641-45, 1992."><meta name="citation_reference" content="Thorens, &quot;Expression cloning of the pancreatic cell receptor for the gluco-incretin hormone glucagon-like peptide 1,&quot; Proc. Natl. Acad. Sci. USA 89:8641-45 (1992)."><meta name="citation_reference" content="Thorens, et al. &quot;Cloning and Functional Expression of the Human Islet GLP-1 Receptor,&quot; Diabetes 42 (11): 1678-82 (1993)."><meta name="citation_reference" content="Turton et al., Nature, vol. 379, pp. 69-72, 1996."><meta name="citation_reference" content="Turton, et al, &quot;A role for glucagon-like peptide-1 in the central regulation of feeding,&quot; Nature 379:69-72 (1996)."><meta name="citation_reference" content="Vandermeers et al, European Journal of Biochemistry, 1987, vol. 164, pp. 321-327."><meta name="citation_reference" content="Veale, P.R., et al, &quot;The presence of islet amyloid polypeptide/calcitonin gen-related peptide/salmon calcitonin binding sites in the rat nucleus accumbens,&quot; European Journal of Pharmacology 262:133-141 (1994)."><meta name="citation_reference" content="Wang et al. &quot;Glucagon-like Peptide-1 Is a Physiological Incretin in Rat,&quot; J. Clin. Invest., 95:417-21 (1995)."><meta name="citation_reference" content="Wang, Y.J. and Hanson, M.A. &quot;Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers,&quot; Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S, 1988."><meta name="citation_reference" content="Watson, N., et al, &quot;Effects of captopril on glucose tolerance in elderly patients with congestive cardiac failure,&quot; Current Medical Research and Opinion 12(6):374-378 (1991)."><meta name="citation_reference" content="Wettergren et al. &quot;Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man,&quot; Dig Dis Sci 38 (4): 665-73 (1993)."><meta name="citation_reference" content="Willms et al. &quot;Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Mel: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients,&quot; J. Clin. Endocrinol. Metab. 81(1):327-32 (1996)."><meta name="citation_reference" content="Young, et al, Program and Abstracts, 10&lt;SUP&gt;th &lt;/SUP&gt;International Congress of Endocrinology Jun. 12-15, 1996, San Francisco, p. 419 (P2-58)."><meta name="citation_patent_number" content="US:7297761"><meta name="citation_patent_application_number" content="US:10/894,999"><link rel="canonical" href="http://www.google.com/patents/US7297761"/><meta property="og:url" content="http://www.google.com/patents/US7297761"/><meta name="title" content="Patent US7297761 - Pharmaceutical compositions containing exendins"/><meta name="description" content="Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed."/><meta property="og:title" content="Patent US7297761 - Pharmaceutical compositions containing exendins"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("HobtU5H_OtLMsQTfhwI"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("GBR"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("HobtU5H_OtLMsQTfhwI"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("GBR"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us7297761?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US7297761"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=XXt_BAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS7297761&amp;usg=AFQjCNGILDcIxv4HnmAF-I5PnLWFRLPwSA" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US7297761.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US7297761.pdf"></a><a class="appbar-application-grant-link" data-label="Application" href="/patents/US20050215469"></a><a class="appbar-application-grant-link" data-selected="true" data-label="Grant" href="/patents/US7297761"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US7297761" style="display:none"><span itemprop="description">Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful...</span><span itemprop="url">http://www.google.com/patents/US7297761?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US7297761 - Pharmaceutical compositions containing exendins</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US7297761 - Pharmaceutical compositions containing exendins" title="Patent US7297761 - Pharmaceutical compositions containing exendins"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US7297761 B2</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 10/894,999</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Nov 20, 2007</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Jul 19, 2004</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Aug 8, 1996</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2277112A1">CA2277112A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2277112C">CA2277112C</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69831673D1">DE69831673D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69831673T2">DE69831673T2</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE122007000044I1">DE122007000044I1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE122007000044I2">DE122007000044I2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0996459A1">EP0996459A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0996459A4">EP0996459A4</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0996459B1">EP0996459B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1629849A2">EP1629849A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1629849A3">EP1629849A3</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1629849B1">EP1629849B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6956026">US6956026</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6989366">US6989366</a>, </span><span class="patent-bibdata-value"><a href="/patents/US7115569">US7115569</a>, </span><span class="patent-bibdata-value"><a href="/patents/US7138375">US7138375</a>, </span><span class="patent-bibdata-value"><a href="/patents/US7419952">US7419952</a>, </span><span class="patent-bibdata-value"><a href="/patents/US7700549">US7700549</a>, </span><span class="patent-bibdata-value"><a href="/patents/US7741269">US7741269</a>, </span><span class="patent-bibdata-value"><a href="/patents/US8288338">US8288338</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20020137666">US20020137666</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20030087821">US20030087821</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20050043238">US20050043238</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20050059601">US20050059601</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20050101537">US20050101537</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20050215469">US20050215469</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20060148713">US20060148713</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20090176704">US20090176704</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20110034377">US20110034377</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20130023470">US20130023470</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1998030231A1">WO1998030231A1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">10894999, </span><span class="patent-bibdata-value">894999, </span><span class="patent-bibdata-value">US 7297761 B2, </span><span class="patent-bibdata-value">US 7297761B2, </span><span class="patent-bibdata-value">US-B2-7297761, </span><span class="patent-bibdata-value">US7297761 B2, </span><span class="patent-bibdata-value">US7297761B2</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Nigel+Robert+Arnold+Beeley%22">Nigel Robert Arnold Beeley</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Kathryn+S.+Prickett%22">Kathryn S. Prickett</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Sunil+Bhavsar%22">Sunil Bhavsar</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Andrew+Young%22">Andrew Young</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Bronislava+Gedulin%22">Bronislava Gedulin</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Amylin+Pharmaceuticals,+Inc.%22">Amylin Pharmaceuticals, Inc.</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US7297761.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US7297761.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US7297761.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (24),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (71),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (10),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (40),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (9)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/7297761&usg=AFQjCNGSZb-aKyDwos-LXxTkN8lZlt-Q6A">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D7297761&usg=AFQjCNESbE0inwG-vPa_6zrUmc66V19GIw">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D7297761B2%26KC%3DB2%26FT%3DD&usg=AFQjCNEYxHIwtjEkFZTk43d2_FoK3z9Tkw">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT55814676" lang="EN" load-source="patent-office">Pharmaceutical compositions containing exendins</invention-title></span><br><span class="patent-number">US 7297761 B2</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA51230340" lang="EN" load-source="patent-office"> <div num="p-0001" class="abstract">Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(11)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7297761B2/US07297761-20071120-D00001.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7297761B2/US07297761-20071120-D00001.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7297761B2/US07297761-20071120-D00002.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7297761B2/US07297761-20071120-D00002.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7297761B2/US07297761-20071120-D00003.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7297761B2/US07297761-20071120-D00003.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7297761B2/US07297761-20071120-D00004.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7297761B2/US07297761-20071120-D00004.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7297761B2/US07297761-20071120-D00005.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7297761B2/US07297761-20071120-D00005.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7297761B2/US07297761-20071120-D00006.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7297761B2/US07297761-20071120-D00006.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7297761B2/US07297761-20071120-D00007.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7297761B2/US07297761-20071120-D00007.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7297761B2/US07297761-20071120-D00008.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7297761B2/US07297761-20071120-D00008.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7297761B2/US07297761-20071120-D00009.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7297761B2/US07297761-20071120-D00009.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7297761B2/US07297761-20071120-D00010.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7297761B2/US07297761-20071120-D00010.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7297761B2/US07297761-20071120-D00011.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7297761B2/US07297761-20071120-D00011.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(37)</span></span></div><div class="patent-text"><div mxw-id="PCLM9301881" lang="EN" load-source="patent-office" class="claims">
    <div class="claim"> <div id="CLM-00001" num="00001" class="claim">
      <div class="claim-text">1. A pharmaceutical composition comprising an exendin-4 and an acetate buffer.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00002" num="00002" class="claim">
      <div class="claim-text">2. The composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said composition has a pH from about 3.5 to about 5.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00003" num="00003" class="claim">
      <div class="claim-text">3. The composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said pH is about 4.5.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00004" num="00004" class="claim">
      <div class="claim-text">4. The composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising an isotonicity agent.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00005" num="00005" class="claim">
      <div class="claim-text">5. The composition of <claim-ref idref="CLM-00004">claim 4</claim-ref>, wherein said isotonicity agent is selected from the group consisting of sodium chloride, dextrose, boric acid, sodium tartrate, propylene glycol, polyols, and any combination thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00006" num="00006" class="claim">
      <div class="claim-text">6. The composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising a pharmaceutically acceptable carrier or excipient selected from the group consisting of calcium carbonate, calcium phosphate, lactose, glucose, sucrose, starch, cellulose derivatives, gelatin, oils, polyethylene glycol, and any combination thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00007" num="00007" class="claim">
      <div class="claim-text">7. The composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising at least one additional substance other than an exendin that reduces food intake, appetite, body weight, obesity or any combination thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00008" num="00008" class="claim">
      <div class="claim-text">8. The composition of <claim-ref idref="CLM-00007">claim 7</claim-ref>, wherein said at least one additional substance is selected from the group consisting of amylin, an amylin agonist, a leptin, a cholecystokinin (CCK), CCK-8, a calcitonin, and any combination thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00009" num="00009" class="claim">
      <div class="claim-text">9. The composition of <claim-ref idref="CLM-00007">claim 7</claim-ref>, wherein said at least one additional substance comprises human amylin.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00010" num="00010" class="claim">
      <div class="claim-text">10. The composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said composition is formulated to provide a daily dose of from about 0.1 μg/kg to about 100 μg/kg of said exendin in a single or divided dose.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00011" num="00011" class="claim">
      <div class="claim-text">11. The composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said composition is formulated to provide a daily dose of from about 0.1 μg/kg to about 10 μg/kg of said exendin in a single or divided dose.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00012" num="00012" class="claim">
      <div class="claim-text">12. The composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said composition is formulated to provide a daily dose of from about 0.1 μg/kg to about 1 μg/kg of said exendin in a single or divided dose.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00013" num="00013" class="claim">
      <div class="claim-text">13. The composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said composition is formulated to provide a daily dose of from about 0.01 mg to about 5 mg of said exendin in a single or divided dose.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00014" num="00014" class="claim">
      <div class="claim-text">14. The composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said composition is formulated to provide a daily dose of from about 0.01 mg to about 2 mg of said exendin in a single or divided dose.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00015" num="00015" class="claim">
      <div class="claim-text">15. The composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said composition is formulated to provide a daily dose of from about 0.01 mg to about 1 mg of said exendin in a single or divided dose.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00016" num="00016" class="claim">
      <div class="claim-text">16. The composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said composition is formulated to provide a daily dose of from about 0.01 mg to about 0.5 mg of said exendin in a single or divided dose.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00017" num="00017" class="claim">
      <div class="claim-text">17. The composition of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said composition is formulated for intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical, transmucosal or pulmonary administration.</div>
    </div>
    </div> <div class="claim"> <div id="CLM-00018" num="00018" class="claim">
      <div class="claim-text">18. A pharmaceutical composition comprising exendin-4, mannitol, and an acetate buffer, wherein said composition has a pH from about 3.5 to about 5.0.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00019" num="00019" class="claim">
      <div class="claim-text">19. The composition of <claim-ref idref="CLM-00018">claim 18</claim-ref>, wherein said composition is formulated to provide a daily dose of from about 0.1 μg/kg to about 1 μg/kg of said exendin-4 in a single or divided dose.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00020" num="00020" class="claim">
      <div class="claim-text">20. The composition of <claim-ref idref="CLM-00018">claim 18</claim-ref>, wherein said composition is formulated to provide a daily dose of from about 0.01 mg to about 0.5 mg of said exendin-4 in a single or divided dose.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00021" num="00021" class="claim">
      <div class="claim-text">21. The composition of <claim-ref idref="CLM-00018">claim 18</claim-ref>, further comprising at least one additional substance other than an exendin that reduces food intake, appetite, body weight, obesity or any combination thereof.</div>
    </div>
    </div> <div class="claim"> <div id="CLM-00022" num="00022" class="claim">
      <div class="claim-text">22. A pharmaceutical composition comprising a buffer and an exendin selected from at least one of the group consisting of an exendin-3, and an exendin-4, wherein said composition has a pH from about 3.5 to about 5.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00023" num="00023" class="claim">
      <div class="claim-text">23. The composition of <claim-ref idref="CLM-00022">claim 22</claim-ref>, wherein said buffer comprises an acetate buffer.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00024" num="00024" class="claim">
      <div class="claim-text">24. The composition of <claim-ref idref="CLM-00022">claim 22</claim-ref>, further comprising an isotonicity agent.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00025" num="00025" class="claim">
      <div class="claim-text">25. The composition of <claim-ref idref="CLM-00022">claim 22</claim-ref>, wherein said isotonicity agent is selected from the group consisting of sodium chloride, dextrose, boric acid, sodium tartrate, propylene glycol, polyols, and any combination thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00026" num="00026" class="claim">
      <div class="claim-text">26. The composition of <claim-ref idref="CLM-00022">claim 22</claim-ref>, further comprising a pharmaceutically acceptable carrier or excipient selected from the group consisting of calcium carbonate, calcium phosphate, lactose, glucose, sucrose, starch, cellulose derivatives, gelatin, oils, polyethylene glycol, and any combination thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00027" num="00027" class="claim">
      <div class="claim-text">27. The composition of <claim-ref idref="CLM-00022">claim 22</claim-ref>, further comprising at least one additional substance other than an exendin that reduces food intake, appetite, body weight, obesity or any combination thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00028" num="00028" class="claim">
      <div class="claim-text">28. The composition of <claim-ref idref="CLM-00027">claim 27</claim-ref>, wherein said at least one additional substance is selected from the group consisting of amylin, an amylin agonist, a leptin, a cholecystokinin (CCK), CCK-8, a calcitonin, and any combination thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00029" num="00029" class="claim">
      <div class="claim-text">29. The composition of <claim-ref idref="CLM-00027">claim 27</claim-ref>, wherein said at least one additional substance comprises human amylin.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00030" num="00030" class="claim">
      <div class="claim-text">30. The composition of <claim-ref idref="CLM-00022">claim 22</claim-ref>, wherein said composition is formulated to provide a daily dose of from about 0.1 μg/kg to about 100 μg/kg of said exendin in a single or divided dose.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00031" num="00031" class="claim">
      <div class="claim-text">31. The composition of <claim-ref idref="CLM-00022">claim 22</claim-ref>, wherein said composition is formulated to provide a daily dose of from about 0.1 μg/kg to about 10 μg/kg of said exendin in a single or divided dose.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00032" num="00032" class="claim">
      <div class="claim-text">32. The composition of <claim-ref idref="CLM-00022">claim 22</claim-ref>, wherein said composition is formulated to provide a daily dose of from about 0.1 μg/kg to about 1 μg/kg of said exendin in a single or divided dose.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00033" num="00033" class="claim">
      <div class="claim-text">33. The composition of <claim-ref idref="CLM-00022">claim 22</claim-ref>, wherein said composition is formulated to provide a daily dose of from about 0.01 mg to about 0.5 mg of said exendin in a single or divided dose.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00034" num="00034" class="claim">
      <div class="claim-text">34. The composition of <claim-ref idref="CLM-00022">claim 22</claim-ref>, wherein said composition is formulated to provide a daily dose of from about 0.01 mg to about 0.5 mg of said exendin in a single or divided dose.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00035" num="00035" class="claim">
      <div class="claim-text">35. The composition of <claim-ref idref="CLM-00022">claim 22</claim-ref>, wherein said composition is formulated for intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical, transmucosal or pulmonary administration.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00036" num="00036" class="claim">
      <div class="claim-text">36. The pharmaceutical composition of <claim-ref idref="CLM-00022">claim 22</claim-ref>, wherein said exendin-4 is selected from the group consisting of exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, <sub>14</sub>Leu, <sup>25</sup>Phe exendin-4 amide, <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4 (1-28) amide, <sup>14</sup>Leu, <sup>22</sup>Ala, <sup>25</sup>Phe exendin-4 (1-28) amide, and any combination thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00037" num="00037" class="claim">
      <div class="claim-text">37. The pharmaceutical composition of <claim-ref idref="CLM-00022">claim 22</claim-ref>, wherein said exendin is exendin-4.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES16324425" lang="EN" load-source="patent-office" class="description">
    <p num="p-0002">This application is a continuation of U.S. patent application Ser. No. 09/003.869, filed Jan. 7, 1998 now U.S. Pat. No. 6,956,026, which claims the benefit of U.S. Provisional Application No. 60/034,905, filed Jan. 7, 1997; U.S. Provisional Application No. 60/055,404, filed Aug. 8, 1997; U.S. Provisional Application No. 60/066,029, filed Nov. 14, 1997; and U.S. Provisional Application No. 60/065,442, filed Nov. 14, 1997; each of which is incorporated by reference in their entirety for all purposes. This application is also a continuation-in-part of U.S. patent application Ser. No. 08/908,867, filed Aug. 8, 1997 now U.S. Pat. No. 6,858,576, which is a continuation-in-part of U.S. patent application Ser. No. 08/694,954, filed Aug. 8, 1996, now abandoned, both of which are incorporated by reference in their entirety for all purposes.</p>
    <heading>FIELD OF THE INVENTION</heading> <p num="p-0003">The present invention relates to methods for treating conditions or disorders which can be alleviated by reducing food intake comprising administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other compounds or compositions that affect satiety such as a leptin or an amylin agonist. The methods are useful for treating conditions or disorders, in which the reduction of food intake is of value, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.</p>
    <heading>BACKGROUND</heading> <p num="p-0004">The following description summarizes information relevant to the present invention. It is not an admission that any of the information provided herein is prior art to the presently claimed invention, nor that any of the publications specifically or implicitly referenced are prior art to that invention.</p>
    <heading>Exendin</heading> <p num="p-0005">Exendins are peptides that are found in the venom of the Gila-monster, a lizard found in Arizona, and the Mexican Beaded Lizard. Exendin-3 is present in the venom of <i>Heloderma horridum</i>, and exendin-4 is present in the venom of <i>Heloderma suspectum </i>(Eng, J., et al., <i>J. Biol. Chem., </i>265:20259-62, 1990; Eng., J., et al., <i>J. Biol. Chem., </i>267:7402-05, 1992). The exendins have some sequence similarity to several members of the glucagon-like peptide family, with the highest homology, 53%, being to glucagon-like peptide-1 (7-36) GLP-1[7-36]NH<sub>2 </sub>(Goke, et al., <i>J. Biol. Chem., </i>268:19650-55, 1993). GLP-1[7-36]NH<sub>2</sub>, also known as proglucagon [78-107], has an insulinotropic effect, stimulating insulin secretion from pancreatic β-cells; GLP also inhibits glucagon secretion from pancreatic α-cells (Orskov, et al., <i>Diabetes, </i>42:658-61, 1993; D'Alessio, et al., <i>J. Clin. Invest., </i>97:133-38, 1996). GLP-1 is reported to inhibit gastric emptying (Williams B, et al., <i>J Clin Endocrinol Metab </i>81 (1): 327-32, 1996; Wettergren A, et al., <i>Dig Dis Sci </i>38 (4): 665-73, 1993), and gastric acid secretion. (Schjoldager B T, et al., <i>Dig Dis Sci </i>34 (5): 703-8, 1989; O'Halloran D J, et al., <i>J Endocrinol </i>126 (1): 169-73, 1990; Wettergren A, et al., <i>Dig Dis Sci </i>38 (4): 665-73, 1993). GLP-1[7-37], which has an additional glycine residue at its carboxy terminus, also stimulates insulin secretion in humans (Orskov, et al., <i>Diabetes, </i>42:658-61, 1993). A transmembrane G-protein adenylate-cyclase-coupled receptor believed to be responsible for the insulinotropic effect of GLP-1 is reported to have been cloned from a β-cell line (Thorens, Proc. Natl. Acad. Sci. USA 89:8641-45 (1992)).</p>
    <p num="p-0006">Exendin-4 potently binds at GLP-1 receptors on insulin-secreting βTC1 cells, at dispersed acinar cells from guinea pig pancreas, and at parietal cells from stomach; the peptide is also said to stimulate somatostatin release and inhibit gastrin release in isolated stomachs (Goke, et al., <i>J. Biol. Chem. </i>268:19650-55, 1993; Schepp, et al., <i>Eur. J. Pharmacol., </i>69:183-91, 1994; Eissele, et al., <i>Life Sci., </i>55:629-34, 1994). Exendin-3 and exendin-4 were reported to stimulate cAMP production in, and amylase release from, pancreatic acinar cells (Malhotra, R., et al., <i>Regulatory Peptides, </i>41:149-56, 1992; Raufman, et al., <i>J. Biol. Chem. </i>267:21432-37, 1992; Singh, et al., <i>Regul. Pept. </i>53:47-59, 1994). The use of exendin-3 and exendin-4 as insulinotrophic agents for the treatment of diabetes mellitus and the prevention of hyperglycemia has been proposed (Eng, U.S. Pat. No. 5,424,286).</p>
    <p num="p-0007">C-terminally truncated exendin peptides such as exendin[9-39], a carboxyamidated molecule, and fragments 3-39 through 9-39 have been reported to be potent and selective antagonists of GLP-1 (Goke, et al., <i>J. Biol. Chem., </i>268:19650-55, 1993; Raufman, J. P., et al., <i>J. Biol. Chem. </i>266:2897-902, 1991; Schepp, W., et al., <i>Eur. J. Pharm. </i>269:183-91, 1994; Montrose-Rafizadeh, et al., <i>Diabetes, </i>45(Suppl. 2):152A, 1996). Exendin[9-39] is said to block endogenous GLP-1 in vivo, resulting in reduced insulin secretion. Wang, et al., <i>J. Clin. Invest., </i>95:417-21, 1995; D'Alessio, et al., <i>J. Clin. Invest., </i>97:133-38, 1996). The receptor apparently responsible for the insulinotropic effect of GLP-1 has reportedly been cloned from rat pancreatic islet cell (Thorens, B., <i>Proc. Natl. Acad. Sci. USA </i>89:8641-8645, 1992). Exendins and exendin[9-39] are said to bind to the cloned GLP-1 receptor (rat pancreatic β-cell GLP-1 receptor (Fehmann H C, et al., <i>Peptides </i>15 (3): 453-6, 1994) and human GLP-1 receptor (Thorens B, et al., <i>Diabetes </i>42 (11): 1678-82, 1993). In cells transfected with the cloned GLP-1 receptor, exendin-4 is reportedly an agonist, i.e., it increases cAMP, while exendin[9-39] is identified as an antagonist, i.e., it blocks the stimulatory actions of exendin-4 and GLP-1. Id.</p>
    <p num="p-0008">Exendin[9-39] is also reported to act as an antagonist of the full length exendins, inhibiting stimulation of pancreatic acinar cells by exendin-3 and exendin-4 (Raufman, et al., <i>J. Biol. Chem. </i>266:2897-902, 1991; Raufman, et al., <i>J. Biol. Chem., </i>266:21432-37, 1992). It is also reported that exendin[9-39] inhibits the stimulation of plasma insulin levels by exendin-4, and inhibits the somatostatin release-stimulating and gastrin release-inhibiting activities of exendin-4 and GLP-1 (Kolligs, F., et al., <i>Diabetes, </i>44:16-19, 1995; Eissele, et al., <i>Life Sciences, </i>55:629-34, 1994).</p>
    <p num="p-0009">Exendins have recently been found to inhibit gastric emptying (U.S. Ser. No. 08/694,954, filed Aug. 8, 1996, which enjoys common ownership with the present invention and is hereby incorporated by reference).</p>
    <p num="p-0010">Exendin [9-39] has been used to investigate the physiological relevance of central GLP-1 in control of food intake (Turton, M. D. et al. <i>Nature </i>379:69-72, 1996). GLP-1 administered by intracerebroventricular (ICV) injection inhibits food intake in rats. This satiety-inducing effect of GLP-1 delivered ICV is reported to be inhibited by ICV injection of exendin [9-39] (Turton, supra). However, it has been reported that GLP-1 does not inhibit food intake in mice when administered by peripheral injection (Turton, M. D., <i>Nature </i>379:69-72, 1996; Bhavsar, S. P., <i>Soc. Neurosci. Abstr. </i>21:460 (188.8), 1995).</p>
    <heading>Obesity and Hypernutrition</heading> <p num="p-0011">Obesity, excess adipose tissue, is becoming increasingly prevalent in developed societies. For example, approximately 30% of adults in the U.S. were estimated to be 20 percent above desirable body weight—an accepted measure of obesity sufficient to impact a health risk (<i>Harrison's Principles of Internal Medicine </i>12<i>th Edition</i>, McGraw Hill, Inc. (1991) p. 411). The pathogenesis of obesity is believed to be multifactorial but the basic problem is that in obese subjects food intake and energy expenditure do not come into balance until there is excess adipose tissue. Attempts to reduce food intake, or hypernutrition, are usually fruitless in the medium term because the weight loss induced by dieting results in both increased appetite and decreased energy expenditure (Leibel et al., (1995) <i>New England Journal of Medicine </i>322: 621-628). The intensity of physical exercise required to expend enough energy to materially lose adipose mass is too great for most people to undertake on a sufficiently frequent basis. Thus, obesity is currently a poorly treatable, chronic, essentially intractable metabolic disorder. Not only is obesity itself believed by some to be undesirable for cosmetic reasons, but obesity also carries serious risk of co-morbidities including, Type 2 diabetes, increased cardiac risk, hypertension, atherosclerosis, degenerative arthritis, and increased incidence of complications of surgery involving general anesthesia obesity due to hypernutrition is also a risk factor for the group of conditions called insulin resistance syndrome, or “syndrome X.” In syndrome X, it has been reported that there is a linkage between insulin resistance and hypertension. (Watson N. and Sandler M., <i>Curr. Med. Res. Opin., </i>12(6):374-378 (1991); Kodama J. et al., <i>Diabetes Care, </i>13(11):1109-1111 (1990); Lithell et al., <i>J. Cardiovasc. Pharmacol., </i>15 Suppl. 5:S46-S52 (1990)).</p>
    <p num="p-0012">In those few subjects who do succeed in losing weight, by about 10 percent of body weight, there can be striking improvements in co-morbid conditions, most especially Type 2 diabetes in which dieting and weight loss are the primary therapeutic modality, albeit relatively ineffective in many patients for the reasons stated above. Reducing food intake in obese subjects would decrease the plasma glucose level, the plasma lipid level, and the cardiac risk in these subjects. Hypernutrition is also the result of, and the psychological cause of, many eating disorders. Reducing food intake would also be beneficial in the treatment of such disorders.</p>
    <p num="p-0013">Thus, it can be appreciated that an effective means to reduce food intake is a major challenge and a superior method of treatment would be of great utility. Such a method, and compounds and compositions which are useful therefor, have been invented and are described and claimed herein.</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p num="p-0014">The present invention concerns the surprising discovery that exendins and exendin agonists have a profound and prolonged effect on inhibiting food intake.</p>
    <p num="p-0015">The present invention is directed to novel methods for treating conditions or disorders associated with hypernutrition, comprising the administration of an exendin, for example, exendin-3 [SEQ ID NO. 1: His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser], or exendin-4 [SEQ ID NO. 2: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser], or other compounds which effectively bind to the receptor at which exendin exerts its action on reducing food intake. These methods will be useful in the treatment of, for example, obesity, diabetes, including Type II or non-insulin dependent diabetes, eating disorders, and insulin-resistance syndrome.</p>
    <p num="p-0016">In a first aspect, the invention features a method of treating conditions or disorders which can be alleviated by reducing food intake in a subject comprising administering to the subject a therapeutically effective amount of an exendin or an exendin agonist. By an “exendin agonist” is meant a compound that mimics the effects of exendin on the reduction of food intake by binding to the receptor or receptors where exendin causes this effect. Preferred exendin agonist compounds include those described in U.S. Provisional Patent Application Ser. No. 60/055,404, entitled, “Novel Exendin Agonist Compounds,” filed Aug. 8, 1997; U.S. Provisional Patent Application Ser. No. 60/065,442, entitled, “Novel Exendin Agonist Compounds,” filed Nov. 14, 1997; and U.S. Provisional Patent Application Ser. No. 60/066,029, entitled, “Novel Exendin Agonist Compounds,” filed Nov. 14, 1997; all of which enjoy common ownership with the present application and all of which are incorporated by this reference into the present application as though fully set forth herein. By “condition or disorder which can be alleviated by reducing food intake” is meant any condition or disorder in a subject that is either caused by, complicated by, or aggravated by a relatively high food intake, or that can be alleviated by reducing food intake. Such conditions or disorders include, but are not limited to, obesity, diabetes, including Type II diabetes, eating disorders, and insulin-resistance syndrome.</p>
    <p num="p-0017">Thus, in a first embodiment, the present invention provides a method for treating conditions or disorders which can be alleviated by reducing food intake in a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist. Preferred exendin agonist compounds include those described in U.S. Provisional Patent Application Ser. Nos. 60/055,404; 60/065,442; and 60/066,029, which have been incorporated by reference in the present application. Preferably, the subject is a vertebrate, more preferably a mammal, and most preferably a human. In preferred aspects, the exendin or exendin agonist is administered parenterally, more preferably by injection. In a most preferred aspect, the injection is a peripheral injection. Preferably, about 10 μg-30 μg to about 5 mg of the exendin or exendin agonist is administered per day. More preferably, about 10-30 μg to about 2 mg, or about 10-30 μg to about 1 mg of the exendin or exendin agonist is administered per day. Most preferably, about 30 μg to about 500 μg of the exendin or exendin agonist is administered per day.</p>
    <p num="p-0018">In various preferred embodiments of the invention, the condition or disorder is obesity, diabetes, preferably Type II diabetes, an eating disorder, or insulin-resistance syndrome.</p>
    <p num="p-0019">In other preferred aspects of the invention, a method is provided for reducing the appetite of a subject comprising administering to said subject an appetite-lowering amount of an exendin or an exendin agonist.</p>
    <p num="p-0020">In yet other preferred aspects, a method is provided for lowering plasma lipids comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.</p>
    <p num="p-0021">The methods of the present invention may also be used to reduce the cardiac risk of a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist. In one preferred aspect, the exendin or exendin agonist used in the methods of the present invention is exendin-3. In another preferred aspect, said exendin is exendin-4. Other preferred exendin agonists include exendin-4 (1-30) [SEQ ID NO 6: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly], exendin-4 (1-30) amide [SEQ ID NO 7: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly-NH<sub>2</sub>], exendin-4 (1-28) amide [SEQ ID NO 40: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH<sub>2</sub>], <sup>14</sup>Leu,<sup>25</sup>Phe exendin-4 amide [SEQ ID NO 9: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser-NH<sub>2</sub>], <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4 (1-28) amide [SEQ ID NO 41: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH<sub>2</sub>], and <sup>14</sup>Leu, <sup>22</sup>Ala,<sup>25</sup>Phe exendin-4 (1-28) amide [SEQ ID NO 8: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Ala Ile Glu Phe Leu Lys Asn-NH<sub>2</sub>].</p>
    <p num="p-0022">In the methods of the present invention, the exendins and exendin agonists may be administered separately or together with one or more other compounds and compositions that exhibit a long term or short-term satiety action, including, but not limited to other compounds and compositions that comprise an amylin agonist, cholecystokinin (CCK), or a leptin (ob protein). Suitable amylin agonists include, for example, [<sup>25,28,29</sup>Pro-]-human amylin (also known as “pramlintide,” and previously referred to as “AC-137”) as described in “Amylin Agonist Peptides and Uses Therefor,” U.S. Pat. No. 5,686,511, issued Nov. 11, 1997, and salmon calcitonin. The CCK used is preferably CCK octopeptide (CCK-8). Leptin is discussed in, for example, Pelleymounter, M. A., et al. <i>Science </i>269:540-43 (1995); Halaas, J. L., et al. <i>Science </i>269:543-46 (1995); and Campfield, L. A., et al. <i>Eur. J. Pharmac. </i>262:133-41 (1994).</p>
    <p num="p-0023">In other embodiments of the invention is provided a pharmaceutical composition for use in the treatment of conditions or disorders which can be alleviated by reducing food intake comprising a therapeutically effective amount of an exendin or exendin agonist in association with a pharmaceutically acceptable carrier. Preferably, the pharmaceutical composition comprises a therapeutically effective amount for a human subject.</p>
    <p num="p-0024">The pharmaceutical composition may preferably be used for reducing the appetite of a subject, reducing the weight of a subject, lowering the plasma lipid level of a subject, or reducing the cardiac risk of a subject. Those of skill in the art will recognize that the pharmaceutical composition will preferably comprise a therapeutically effective amount of an exendin or exendin agonist to accomplish the desired effect in the subject.</p>
    <p num="p-0025">The pharmaceutical compositions may further comprise one or more other compounds and compositions that exhibit a long-term or short-term satiety action, including, but not limited to other compounds and compositions that comprise an amylin agonist, CCK, preferably CCK-8, or leptin. Suitable amylin agonists include, for example, [<sup>25,28,29</sup>Pro]-human amylin and salmon calcitonin.</p>
    <p num="p-0026">In one preferred aspect, the pharmaceutical composition comprises exendin-3. In another preferred aspect, the pharmaceutical composition comprises exendin-4. In other preferred aspects, the pharmaceutical compositions comprises a peptide selected from: exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, <sup>14</sup>Leu,<sup>25</sup>Phe exendin-4 amide, <sup>14</sup>Leu,<sup>25</sup>Phe exendin-4 (1-28) amide, and <sup>14</sup>Leu,<sup>22</sup>Ala,<sup>25</sup>Phe exendin-4 (1-28) amide.</p>
    <description-of-drawings> <heading>BRIEF DESCRIPTION OF THE DRAWINGS</heading> <p num="p-0027"> <figref idrefs="DRAWINGS">FIG. 1</figref> is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of exendin-4 and GLP-1.</p>
      <p num="p-0028"> <figref idrefs="DRAWINGS">FIG. 2</figref> is a graphical depiction of the change of food intake in obese mice after intraperitoneal injection of exendin-4.</p>
      <p num="p-0029"> <figref idrefs="DRAWINGS">FIG. 3</figref> is a graphical depiction of the change of food intake in rats at 2 hours, 12 hours and 24 hours after intracerebroventricular injection of exendin-4</p>
      <p num="p-0030"> <figref idrefs="DRAWINGS">FIG. 4</figref> is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of exendin-4 (1-30) (“Compound 1”).</p>
      <p num="p-0031"> <figref idrefs="DRAWINGS">FIG. 5</figref> is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of exendin-4 (1-30) amide (“Compound 2”).</p>
      <p num="p-0032"> <figref idrefs="DRAWINGS">FIG. 6</figref> is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of exendin-4 (1-28) amide (“Compound 3”).</p>
      <p num="p-0033"> <figref idrefs="DRAWINGS">FIG. 7</figref> is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of <sup>14</sup>Leu,<sup>25</sup>Phe exendin4 amide (“Compound 4”).</p>
      <p num="p-0034"> <figref idrefs="DRAWINGS">FIG. 8</figref> is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of <sup>14</sup>Leu,<sup>25</sup>Phe exendin-4 (1-28) amide (“Compound 5”).</p>
      <p num="p-0035"> <figref idrefs="DRAWINGS">FIG. 9</figref> is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of <sup>14</sup>Leu,<sup>22</sup>Ala,<sup>25</sup>Phe exendin-4 (1-28) amide (“Compound 6”).</p>
      <p num="p-0036"> <figref idrefs="DRAWINGS">FIG. 10A</figref> and B depicts the amino acid sequences for certain exendin agonist compounds useful in the present invention (SEQ ID NOS. 9-39).</p>
    </description-of-drawings> <heading>DETAILED DESCRIPTION OF THE INVENTION</heading> <p num="p-0037">Exendins and exendin agonists are useful as described herein in view of their pharmacological properties. Activity as exendin agonists can be indicated by activity in the assays described below. Effects of exendins or exendin agonists on reducing food intake can be identified, evaluated, or screened for, using the methods described in the Examples below, or other methods known in the art for determining effects on food intake or appetite.</p>
    <p num="h-0008">Exendin Agonist Compounds</p>
    <p num="p-0038">Exendin agonist compounds are those described in U.S. Provisional Application No. 60/055,404, including compounds of the formula (I) [SEQ ID NO. 3]:</p>
    <p num="p-0039"> <tables id="TABLE-US-00001" num="00001"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> 1                  5                      10</td> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td">Xaa<sub>1</sub> Xaa<sub>2</sub> Xaa<sub>3</sub> Gly Thr Xaa<sub>4</sub> Xaa<sub>5</sub> Xaa<sub>6</sub> Xaa<sub>7</sub> Xaa<sub>8</sub> </td> </tr> <tr class="description-tr"> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td">                 15                  20</td> </tr> <tr class="description-tr"> <td class="description-td">Ser Lys Gln Xaa<sub>9</sub> Glu Glu Glu Ala Val Arg Leu</td> </tr> <tr class="description-tr"> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td">                  25                    30</td> </tr> <tr class="description-tr"> <td class="description-td">Xaa<sub>10</sub> Xaa<sub>11</sub> Xaa<sub>12</sub> Xaa<sub>13</sub> Leu Lys Asn Gly Gly Xaa<sub>14</sub> </td> </tr> <tr class="description-tr"> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td">            35</td> </tr> <tr class="description-tr"> <td class="description-td">Ser Ser Gly Ala Xaa<sub>15</sub> Xaa<sub>16</sub> Xaa<sub>17</sub> Xaa<sub>18</sub>-Z</td> </tr> </tbody> </tgroup> </table> </tables> <br>
wherein Xaa<sub>1 </sub>is His, Arg or Tyr; Xaa<sub>2 </sub>is Ser, Gly, Ala or Thr; Xaa<sub>3 </sub>is Asp or Glu; Xaa<sub>4 </sub>is Phe, Tyr or naphthylalanine; Xaa<sub>5</sub>, is Thr or Ser; Xaa<sub>6 </sub>is Ser or Thr; Xaa<sub>7 </sub>is Asp or Glu; Xaa<sub>8 </sub>is Leu, Ile, Val, pentylglycine or Met; Xaa<sub>9 </sub>is Leu, Ile, pentylglycine, Val or Met; Xaa<sub>10 </sub>is Phe, Tyr or naphthylalanine; Xaa<sub>11 </sub>is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met; Xaa<sub>12 </sub>is Glu or Asp; Xaa<sub>13 </sub>is Trp, Phe, Tyr, or naphthylalanine; Xaa<sub>14</sub>, Xaa<sub>15</sub>, Xaa<sub>16 </sub>and Xaa<sub>17 </sub>are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine; Xaa<sub>18 </sub>is Ser, Thr or Tyr; and Z is —OH or —NH<sub>2</sub>; with the proviso that the compound is not exendin-3 or exindin-4.
</p>
    <p num="p-0040">Preferred N-alkyl groups for N-alkylglycine, N-alkylpentylglycine and N-alkylalanine include lower alkyl groups preferably of 1 to about 6 carbon atoms, more preferably of 1 to 4 carbon atoms. Suitable compounds include those listed in <figref idrefs="DRAWINGS">FIG. 10</figref> having amino acid sequences of SEQ. ID. NOS. 9 to 39.</p>
    <p num="p-0041">Preferred exendin agonist compounds include those wherein Xaa<sub>1 </sub>is His or Tyr. More preferably Xaa<sub>1 </sub>is His.</p>
    <p num="p-0042">Preferred are those compounds wherein Xaa<sub>2 </sub>is Gly.</p>
    <p num="p-0043">Preferred are those compounds wherein Xaa<sub>9 </sub>is Leu, pentylglycine or Met.</p>
    <p num="p-0044">Preferred compounds include those wherein Xaa<sub>13 </sub>is Trp or Phe.</p>
    <p num="p-0045">Also preferred are compounds where Xaa<sub>4 </sub>is Phe or naphthylalanine; Xaa<sub>11 </sub>is Ile or Val and Xaa<sub>14</sub>, Xaa<sub>15</sub>, Xaa<sub>16 </sub>and Xaa<sub>17 </sub>are independently selected from Pro, homoproline, thioproline or N-alkylalanine. Preferably N-alkylalanine has a N-alkyl group of 1 to about 6 carbon atoms.</p>
    <p num="p-0046">According to an especially preferred aspect, Xaa<sub>15</sub>, Xaa<sub>16 </sub>and Xaa<sub>17 </sub>are the same amino acid reside.</p>
    <p num="p-0047">Preferred are compounds wherein Xaa<sub>18 </sub>is Ser or Tyr, more preferably Ser.</p>
    <p num="p-0048">Preferably Z is —NH<sub>2</sub>.</p>
    <p num="p-0049">According to one aspect, preferred are compounds of formula (I) wherein Xaa<sub>1 </sub>is His or Tyr, more preferably His; Xaa<sub>2 </sub>is Gly; Xaa<sub>4 </sub>is Phe or naphthylalanine; Xaa<sub>9 </sub>is Leu, pentylglycine or Met; Xaa<sub>10 </sub>is Phe or naphthylalanine; Xaa<sub>11 </sub>is Ile or Val; Xaa<sub>14</sub>, Xaa<sub>15</sub>, Xaa<sub>16 </sub>and Xaa<sub>17 </sub>are independently selected from Pro, homoproline, thioproline or N-alkylalanine; and Xaa<sub>18 </sub>is Ser or Tyr, more preferably Ser. More preferably Z is —NH<sub>2</sub>.</p>
    <p num="p-0050">According to an especially preferred aspect, especially preferred compounds include those of formula (I) wherein: Xaa<sub>1 </sub>is His or Arg; Xaa<sub>2 </sub>is Gly; Xaa<sub>3 </sub>is Asp or Glu; Xaa<sub>4 </sub>is Phe or napthylalanine; Xaa<sub>5 </sub>is Thr or Ser; Xaa<sub>6 </sub>is Ser or Thr; Xaa<sub>7 </sub>is Asp or Glu; Xaa<sub>8 </sub>is Leu or pentylglycine; Xaa<sub>9 </sub>is Leu or pentylglycine; Xaa<sub>10 </sub>is Phe or naphthylalanine; Xaa<sub>11 </sub>is Ile, Val or t-butyltylglycine; Xaa<sub>12 </sub>is Glu or Asp; Xaa<sub>13 </sub>is Trp or Phe; Xaa<sub>14</sub>, Xaa<sub>15</sub>, Xaa<sub>16</sub>, and Xaa<sub>17 </sub>are independently Pro, homoproline, thioproline, or N-methylalanine; Xaa<sub>18 </sub>is Ser or Tyr: and Z is —OH or —NH<sub>2</sub>; with the proviso that the compound does not have the formula of either SEQ. ID. NOS. 1 or 2. More preferably Z is —NH<sub>2</sub>. Especially preferred compounds include those having the amino acid sequence of SEQ. ID. NOS. 9, 10, 21, 22, 23, 26, 28, 34, 35 and 39.</p>
    <p num="p-0051">According to an especially preferred aspect, provided are compounds where Xaa<sub>9 </sub>is Leu, Ile, Val or pentylglycine, more preferably Leu or pentylglycine, and Xaa<sub>13 </sub>is Phe, Tyr or naphthylalanine, more preferably Phe or naphthylalanine. These compounds will exhibit advantageous duration of action and be less subject to oxidative degration, both in vitro and in vivo, as well as during synthesis of the compound.</p>
    <p num="p-0052">Exendin agonist compounds also include those described in U.S. Provisional Application No. 60/065,442, including compounds of the formula (II) [SEQ ID NO. 4]:</p>
    <p num="p-0053"> <tables id="TABLE-US-00002" num="00002"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Xaa<sub>1</sub> Xaa<sub>2</sub> Xaa<sub>3</sub> Gly Xaa<sub>5</sub> Xaa<sub>6</sub> Xaa<sub>7</sub> Xaa<sub>8</sub> Xaa<sub>9</sub> Xaa<sub>10</sub> </td> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td">Xaa<sub>11</sub> Xaa<sub>12</sub> Xaa<sub>13</sub> Xaa<sub>14</sub> Xaa<sub>15</sub> Xaa<sub>16</sub> Xaa<sub>17</sub> Ala</td> </tr> <tr class="description-tr"> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td">Xaa<sub>19</sub> Xaa<sub>20</sub> Xaa<sub>21</sub> Xaa<sub>22</sub> Xaa<sub>23</sub> Xaa<sub>24</sub> Xaa<sub>25</sub> Xaa<sub>26</sub> </td> </tr> <tr class="description-tr"> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td">Xaa<sub>27</sub> Xaa<sub>28</sub>-Z<sub>1</sub>;</td> </tr> </tbody> </tgroup> </table> </tables> <br>
wherein
</p> <ul> <li id="ul0001-0001" num="0053">Xaa<sub>1 </sub>is His, Arg or Tyr;</li> <li id="ul0001-0002" num="0054">Xaa<sub>2 </sub>is Ser, Gly, Ala or Thr;</li> <li id="ul0001-0003" num="0055">Xaa<sub>3 </sub>is Asp or Glu;</li> <li id="ul0001-0004" num="0056">Xaa<sub>5 </sub>is Ala or Thr;</li> <li id="ul0001-0005" num="0057">Xaa<sub>6 </sub>is Ala, Phe, Tyr or naphthylalanine;</li> <li id="ul0001-0006" num="0058">Xaa<sub>7 </sub>is Thr or Ser;</li> <li id="ul0001-0007" num="0059">Xaa<sub>8 </sub>is Ala, Ser or Thr;</li> <li id="ul0001-0008" num="0060">Xaa<sub>9 </sub>is Asp or Glu;</li> <li id="ul0001-0009" num="0061">Xaa<sub>10 </sub>is Ala, Leu, Ile, Val, pentylglycine or Met;</li> <li id="ul0001-0010" num="0062">Xaa<sub>11 </sub>is Ala or Ser;</li> <li id="ul0001-0011" num="0063">Xaa<sub>12 </sub>is Ala or Lys;</li> <li id="ul0001-0012" num="0064">Xaa<sub>13 </sub>is Ala or Gln;</li> <li id="ul0001-0013" num="0065">Xaa<sub>14 </sub>is Ala, Leu, Ile, pentylglycine, Val or Met;</li> <li id="ul0001-0014" num="0066">Xaa<sub>15 </sub>is Ala or Glu;</li> <li id="ul0001-0015" num="0067">Xaa<sub>16 </sub>is Ala or Glu;</li> <li id="ul0001-0016" num="0068">Xaa<sub>17 </sub>is Ala or Glu;</li> <li id="ul0001-0017" num="0069">Xaa<sub>19 </sub>is Ala or Val;</li> <li id="ul0001-0018" num="0070">Xaa<sub>20 </sub>is Ala or Arg;</li> <li id="ul0001-0019" num="0071">Xaa<sub>21 </sub>is Ala or Leu;</li> <li id="ul0001-0020" num="0072">Xaa<sub>22 </sub>is Ala, Phe, Tyr or naphthylalanine;</li> <li id="ul0001-0021" num="0073">Xaa<sub>23 </sub>is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met;</li> <li id="ul0001-0022" num="0074">Xaa<sub>24 </sub>is Ala, Glu or Asp;</li> <li id="ul0001-0023" num="0075">Xaa<sub>25 </sub>is Ala, Trp, Phe, Tyr or naphthylalanine;</li> <li id="ul0001-0024" num="0076">Xaa<sub>26 </sub>is Ala or Leu;</li> <li id="ul0001-0025" num="0077">Xaa<sub>27 </sub>is Ala or Lys;</li> <li id="ul0001-0026" num="0078">Xaa<sub>28 </sub>is Ala or Asn;</li> <li id="ul0001-0027" num="0079">Z<sub>1 </sub>is —OH,
    <ul> <li id="ul0002-0001" num="0080">—NH<sub>2 </sub> </li> <li id="ul0002-0002" num="0081">Gly-Z<sub>2</sub>,</li> <li id="ul0002-0003" num="0082">Gly Gly-Z<sub>2</sub>,</li> <li id="ul0002-0004" num="0083">Gly Gly Xaa<sub>31</sub>-Z<sub>2</sub>,</li> <li id="ul0002-0005" num="0084">Gly Gly Xaa<sub>31 </sub>Ser-Z<sub>2</sub>,</li> <li id="ul0002-0006" num="0085">Gly Gly Xaa<sub>31 </sub>Ser Ser-Z<sub>2</sub>,</li> <li id="ul0002-0007" num="0086">Gly Gly Xaa<sub>31 </sub>Ser Ser Gly-Z<sub>2</sub>,</li> <li id="ul0002-0008" num="0087">Gly Gly Xaa<sub>31 </sub>Ser Ser Gly Ala-Z<sub>2</sub>,</li> <li id="ul0002-0009" num="0088">Gly Gly Xaa<sub>31 </sub>Ser Ser Gly Ala Xaa<sub>36</sub>-Z<sub>2</sub>,</li> <li id="ul0002-0010" num="0089">Gly Gly Xaa<sub>31 </sub>Ser Ser Gly Ala Xaa<sub>36 </sub>Xaa<sub>37</sub>-Z<sub>2 </sub>or</li> <li id="ul0002-0011" num="0090">Gly Gly Xaa<sub>31 </sub>Ser Ser Gly Ala Xaa<sub>36 </sub>Xaa<sub>37 </sub>Xaa<sub>38</sub>-Z<sub>2</sub>;</li> <li id="ul0002-0012" num="0091">Xaa<sub>31</sub>, Xaa<sub>36</sub>, Xaa<sub>37 </sub>and Xaa<sub>38 </sub>are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline,</li> <li id="ul0002-0013" num="0092">N-alkylglycine, N-alkylpentylglycine or N-alkylalanine; and</li> <li id="ul0002-0014" num="0093">Z<sub>2 </sub>is —OH or —NH<sub>2</sub>;
<br>
provided that no more than three of Xaa<sub>3</sub>, Xaa<sub>5</sub>, Xaa<sub>6</sub>, Xaa<sub>8</sub>, Xaa<sub>10</sub>, Xaa<sub>11</sub>, Xaa<sub>12</sub>, Xaa<sub>13</sub>, Xaa<sub>14</sub>, Xaa<sub>15</sub>, Xaa<sub>16</sub>, Xaa<sub>17</sub>, Xaa<sub>19</sub>, Xaa<sub>20</sub>, Xaa<sub>21</sub>, Xaa<sub>24</sub>, Xaa<sub>25</sub>, Xaa<sub>26</sub>, Xaa<sub>27 </sub>and Xaa<sub>28 </sub>are Ala.
<br>
Preferred N-alkyl groups for N-alkylglycine, N-alkylpentylglycine and N-alkylalanine include lower alkyl groups preferably of 1 to about 6 carbon atoms, more preferably of 1 to 4 carbon atoms.
</li> </ul> </li> </ul> <p num="p-0054">Preferred exendin agonist compounds include those wherein Xaa<sub>1 </sub>is His or Tyr. More preferably Xaa<sub>1 </sub>is His.</p>
    <p num="p-0055">Preferred are those compounds wherein Xaa<sub>2 </sub>is Gly.</p>
    <p num="p-0056">Preferred are those compounds wherein Xaa<sub>14 </sub>is Leu, pentylglycine or Met.</p>
    <p num="p-0057">Preferred compounds are those wherein Xaa<sub>25</sub>, is Trp or Phe.</p>
    <p num="p-0058">Preferred compounds are those where Xaa<sub>6 </sub>is Phe or naphthylalanine; Xaa<sub>22 </sub>is Phe or naphthylalanine and Xaa<sub>23 </sub>is Ile or Val.</p>
    <p num="p-0059">Preferred are compounds wherein Xaa<sub>31</sub>, Xaa<sub>36</sub>, Xaa<sub>37 </sub>and Xaa<sub>38 </sub>are independently selected from Pro, homoproline, thioproline and N-alkylalanine.</p>
    <p num="p-0060">Preferably Z<sub>1 </sub>is —NH<sub>2</sub>.</p>
    <p num="p-0061">Preferable Z<sub>2 </sub>is —NH<sub>2</sub>.</p>
    <p num="p-0062">According to one aspect, preferred are compounds of formula (II) wherein Xaa<sub>1 </sub>is His or Tyr, more preferably His; Xaa<sub>2 </sub>is Gly; Xaa<sub>6 </sub>is Phe or naphthylalanine; Xaa<sub>14 </sub>is Leu, pentylglycine or Met; Xaa<sub>22 </sub>is Phe or naphthylalanine; Xaa<sub>23 </sub>is Ile or Val; Xaa<sub>31</sub>, Xaa<sub>36</sub>, Xaa<sub>37 </sub>and Xaa<sub>38 </sub>are independently selected from Pro, homoproline, thioproline or N-alkylalanine. More preferably Z<sub>1 </sub>is —NH<sub>2</sub>.</p>
    <p num="p-0063">According to an especially preferred aspect, especially preferred compounds include those of formula (II) wherein: Xaa<sub>1 </sub>is His or Arg; Xaa<sub>2 </sub>is Gly or Ala; Xaa<sub>3 </sub>is Asp or Glu; Xaa<sub>5 </sub>is Ala or Thr; Xaa<sub>6 </sub>is Ala, Phe or naphthylalaine; Xaa<sub>7 </sub>is Thr or Ser; Xaa<sub>8 </sub>is Ala, Ser or Thr; Xaa<sub>9 </sub>is Asp or Glu; Xaa<sub>10 </sub>is Ala, Leu or pentylglycine; Xaa<sub>11 </sub>is Ala or Ser; Xaa<sub>12 </sub>is Ala or Lys; Xaa<sub>13 </sub>is Ala or Gln; Xaa<sub>14 </sub>is Ala, Leu or pentylglycine; Xaa<sub>15 </sub>is Ala or Glu; Xaa<sub>16 </sub>is Ala or Glu; Xaa<sub>17 </sub>is Ala or Glu; Xaa<sub>19 </sub>is Ala or Val; Xaa<sub>20 </sub>is Ala or Arg; Xaa<sub>21 </sub>is Ala or Leu; Xaa<sub>22 </sub>is Phe or naphthylalanine; Xaa<sub>23 </sub>is Ile, Val or tert-butylglycine; Xaa<sub>24 </sub>is Ala, Glu or Asp; Xaa<sub>25 </sub>is Ala, Trp or Phe; Xaa<sub>26 </sub>is Ala or Leu; Xaa<sub>27 </sub>is Ala or Lys; Xaa<sub>28 </sub>is Ala or Asn; Z<sub>1 </sub>is —OH, —NH<sub>2</sub>, Gly-Z<sub>2</sub>, Gly Gly-Z<sub>2</sub>, Gly Gly Xaa<sub>31</sub>-Z<sub>2</sub>, Gly Gly Xaa<sub>31 </sub>Ser-Z<sub>2</sub>, Gly Gly Xaa<sub>31 </sub>Ser Ser-Z<sub>2</sub>, Gly Gly Xaa<sub>31 </sub>Ser Ser Gly-Z<sub>2</sub>, Gly Gly Xaa<sub>31 </sub>Ser Ser Gly Ala-Z<sub>2</sub>, Gly Gly Xaa<sub>31 </sub>Ser Ser Gly Ala Xaa<sub>36</sub>-Z<sub>2</sub>, Gly Gly Xaa<sub>31 </sub>Ser Ser Gly Ala Xaa<sub>36 </sub>Xaa<sub>37</sub>-Z<sub>2</sub>, Gly Gly Xaa<sub>31 </sub>Ser Ser Gly Ala Xaa<sub>36 </sub>Xaa<sub>37 </sub>Xaa<sub>38</sub>-Z<sub>2</sub>; Xaa<sub>31</sub>, Xaa<sub>36</sub>, Xaa<sub>37 </sub>and Xaa<sub>38 </sub>being independently Pro, homoproline thioproline or N-methylalanine; and Z<sub>2 </sub>being —OH or —NH<sub>2</sub>; provided that no more than three of Xaa<sub>3</sub>, Xaa<sub>5</sub>, Xaa<sub>6</sub>, Xaa<sub>8</sub>, Xaa<sub>10</sub>, Xaa<sub>11</sub>, Xaa<sub>12</sub>, Xaa<sub>13</sub>, Xaa<sub>14</sub>, Xaa<sub>15</sub>, Xaa<sub>16</sub>, Xaa<sub>17</sub>, Xaa<sub>19</sub>, Xaa<sub>20</sub>, Xaa<sub>21</sub>, Xaa<sub>24</sub>, Xaa<sub>25</sub>, Xaa<sub>26</sub>, Xaa<sub>27 </sub>and Xaa<sub>28 </sub>are Ala. Especially preferred compounds include those having the amino acid sequence of SEQ. ID. NOS. 40-61.</p>
    <p num="p-0064">According to an especially preferred aspect, provided are compounds where Xaa<sub>14 </sub>is Leu, Ile, Val or pentylglycine, more preferably Leu or pentylglycine, and Xaa<sub>25 </sub>is Phe, Tyr or naphthylalanine, more preferably Phe or naphthylalanine. These compounds will be less susceptive to oxidative degration, both in vitro and in vivo, as well as during synthesis of the compound.</p>
    <p num="p-0065">Exendin agonist compounds also include those described in U.S. Provisional Application No. 60/066,029, including compounds of the formula (III) [SEQ ID NO. 5]:</p>
    <p num="p-0066"> <tables id="TABLE-US-00003" num="00003"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Xaa<sub>1</sub> Xaa<sub>2</sub> Xaa<sub>3</sub> Xaa<sub>4</sub> Xaa<sub>5</sub> Xaa<sub>6</sub> Xaa<sub>7</sub> Xaa<sub>8</sub> Xaa<sub>9</sub> Xaa<sub>10</sub> </td> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td">Xaa<sub>11</sub> Xaa<sub>12</sub> Xaa<sub>13</sub> Xaa<sub>14</sub> Xaa<sub>15</sub> Xaa<sub>16</sub> Xaa<sub>17</sub> Ala</td> </tr> <tr class="description-tr"> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td">Xaa<sub>19</sub> Xaa<sub>20</sub> Xaa<sub>21</sub> Xaa<sub>22</sub> Xaa<sub>23</sub> Xaa<sub>24</sub> Xaa<sub>25</sub> Xaa<sub>26</sub> </td> </tr> <tr class="description-tr"> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td">Xaa<sub>27</sub> Xaa<sub>28</sub>-Z<sub>1</sub>;</td> </tr> </tbody> </tgroup> </table> </tables> <br>
wherein
</p> <ul> <li id="ul0003-0001" num="0107">Xaa<sub>1 </sub>is His, Arg, Tyr, Ala, Norval, Val or Norleu;</li> <li id="ul0003-0002" num="0108">Xaa<sub>2 </sub>is Ser, Gly, Ala or Thr;</li> <li id="ul0003-0003" num="0109">Xaa<sub>3 </sub>is Ala, Asp or Glu;</li> <li id="ul0003-0004" num="0110">Xaa<sub>4 </sub>is Ala, Norval, Val, Norleu or Gly;</li> <li id="ul0003-0005" num="0111">Xaa<sub>5 </sub>is Ala or Thr;</li> <li id="ul0003-0006" num="0112">Xaa<sub>6 </sub>is Phe, Tyr or naphthylalanine;</li> <li id="ul0003-0007" num="0113">Xaa<sub>7 </sub>is Thr or Ser;</li> <li id="ul0003-0008" num="0114">Xaa<sub>8 </sub>is Ala, Ser or Thr;</li> <li id="ul0003-0009" num="0115">Xaa<sub>9 </sub>is Ala, Norval, Val, Norleu, Asp or Glu;</li> <li id="ul0003-0010" num="0116">Xaa<sub>10 </sub>is Ala, Leu, Ile, Val, pentylglycine or Met;</li> <li id="ul0003-0011" num="0117">Xaa<sub>11 </sub>is Ala or Ser;</li> <li id="ul0003-0012" num="0118">Xaa<sub>12 </sub>is Ala or Lys;</li> <li id="ul0003-0013" num="0119">Xaa<sub>13 </sub>is Ala or Gln;</li> <li id="ul0003-0014" num="0120">Xaa<sub>14 </sub>is Ala, Leu, Ile, pentylglycine, Val or Met;</li> <li id="ul0003-0015" num="0121">Xaa<sub>15 </sub>is Ala or Glu;</li> <li id="ul0003-0016" num="0122">Xaa<sub>16 </sub>is Ala or Glu;</li> <li id="ul0003-0017" num="0123">Xaa<sub>17 </sub>is Ala or Glu;</li> <li id="ul0003-0018" num="0124">Xaa<sub>19 </sub>is Ala or Val;</li> <li id="ul0003-0019" num="0125">Xaa<sub>20 </sub>is Ala or Arg;</li> <li id="ul0003-0020" num="0126">Xaa<sub>21 </sub>is Ala or Leu;</li> <li id="ul0003-0021" num="0127">Xaa<sub>22 </sub>is Phe, Tyr or naphthylalanine;</li> <li id="ul0003-0022" num="0128">Xaa<sub>23 </sub>is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met;</li> <li id="ul0003-0023" num="0129">Xaa<sub>24 </sub>is Ala, Glu or Asp;</li> <li id="ul0003-0024" num="0130">Xaa<sub>25 </sub>is Ala, Trp, Phe, Tyr or naphthylalanine;</li> <li id="ul0003-0025" num="0131">Xaa<sub>26 </sub>is Ala or Leu;</li> <li id="ul0003-0026" num="0132">Xaa<sub>27 </sub>is Ala or Lys;</li> <li id="ul0003-0027" num="0133">Xaa<sub>28 </sub>is Ala or Asn;</li> <li id="ul0003-0028" num="0134">Z<sub>1 </sub>is —OH,
    <ul> <li id="ul0004-0001" num="0135">—NH<sub>2</sub>,</li> <li id="ul0004-0002" num="0136">Gly-Z<sub>2</sub>,</li> <li id="ul0004-0003" num="0137">Gly Gly-Z<sub>2</sub>,</li> <li id="ul0004-0004" num="0138">Gly Gly Xaa<sub>31</sub>-Z<sub>2</sub>,</li> <li id="ul0004-0005" num="0139">Gly Gly Xaa<sub>31 </sub>Ser-Z<sub>2</sub>,</li> <li id="ul0004-0006" num="0140">Gly Gly Xaa<sub>31 </sub>Ser Ser-Z<sub>2</sub>,</li> <li id="ul0004-0007" num="0141">Gly Gly Xaa<sub>31 </sub>Ser Ser Gly-Z<sub>2</sub>,</li> <li id="ul0004-0008" num="0142">Gly Gly Xaa<sub>31 </sub>Ser Ser Gly Ala-Z<sub>2</sub>,</li> <li id="ul0004-0009" num="0143">Gly Gly Xaa<sub>31 </sub>Ser Ser Gly Ala Xaa<sub>36</sub>-Z<sub>2</sub>,</li> <li id="ul0004-0010" num="0144">Gly Gly Xaa<sub>31 </sub>Ser Ser Gly Ala Xaa<sub>36 </sub>Xaa<sub>37</sub>-Z<sub>2</sub>,</li> <li id="ul0004-0011" num="0145">Gly Gly Xaa<sub>31 </sub>Ser Ser Gly Ala Xaa<sub>36 </sub>Xaa<sub>37 </sub>Xaa<sub>38</sub>-Z<sub>2 </sub>or Gly Gly Xaa<sub>31 </sub>Ser Ser Gly Ala Xaa<sub>36 </sub>Xaa<sub>37 </sub>Xaa<sub>38 </sub>Xaa<sub>39</sub>-Z<sub>2</sub>; wherein</li> <li id="ul0004-0012" num="0146">Xaa<sub>3</sub>l, Xaa<sub>36</sub>, Xaa<sub>37 </sub>and Xaa<sub>38 </sub>are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline,</li> <li id="ul0004-0013" num="0147">N-alkylglycine, N-alkylpentylglycine or</li> <li id="ul0004-0014" num="0148">N-alkylalanine; and</li> <li id="ul0004-0015" num="0149">Z<sub>2 </sub>is —OH or —NH<sub>2</sub>;
<br>
provided that no more than three of Xaa<sub>3</sub>, Xaa<sub>4</sub>, Xaa<sub>5</sub>, Xaa<sub>6</sub>, Xaa8, Xaa<sub>9</sub>, Xaa<sub>10</sub>, Xaa<sub>11</sub>, Xaa<sub>12</sub>, Xaa<sub>13</sub>, Xaa<sub>14</sub>, Xaa<sub>15</sub>, Xaa<sub>16</sub>, Xaa<sub>17</sub>, Xaa<sub>19</sub>, Xaa<sub>20</sub>, Xaa<sub>21</sub>, Xaa<sub>24</sub>, Xaa<sub>25</sub>, Xaa<sub>26</sub>, Xaa<sub>27 </sub>and Xaa<sub>28 </sub>are Ala; and provided also that, if Xaa<sub>1 </sub>is His, Arg or Tyr, then at least one of Xaa<sub>3</sub>, Xaa<sub>4 </sub>and Xaa<sub>9 </sub>is Ala.
<br>
Definitions
</li> </ul> </li> </ul> <p num="p-0067">In accordance with the present invention and as used herein, the following terms are defined to have the following meanings, unless explicitly stated otherwise.</p>
    <p num="p-0068">The term “amino acid” refers to natural amino acids, unnatural amino acids, and amino acid analogs, all in their D and L stereoisomers if their structure allow such stereoisomeric forms. Natural amino acids include alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), cysteine (Cys), glutamine (Gln), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), Lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), typtophan (Trp), tyrosine (Tyr) and valine (Val). Unnatural amino acids include, but are not limited to azetidinecarboxylic acid, 2-aminoadipic acid, 3-aminoadipic acid, beta-alanine, aminopropionic acid, 2-aminobutyric acid, 4-aminobutyric acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-aminoisbutyric acid, 2-aminopimelic acid, tertiary-butylglycine, 2,4-diaminoisobutyric acid, desmosine, 2,2′-diaminopimelic acid, 2,3-diaminopropionic acid, N-ethylglycine, N-ethylasparagine, homoproline, hydroxylysine, allo-hydroxylysine, 3-hydroxyproline, 4-hydroxyproline, isodesmosine, allo-isoleucine, N-methylalanine, N-methylglycine, N-methylisoleucine, N-methylpentylglycine, N-methylvaline, naphthalanine, norvaline, norleucine, ornithine, pentylglycine, pipecolic acid and thioproline. Amino acid analogs include the natural and unnatural amino acids which are chemically blocked, reversibly or irreversibly, or modified on their N-terminal amino group or their side-chain groups, as for example, methionine sulfoxide, methionine sulfone, S-(carboxymethyl)-cysteine, S-(carboxymethyl)-cysteine sulfoxide and S-(carboxymethyl)-cysteine sulfone.</p>
    <p num="p-0069">The term “amino acid analog” refers to an amino acid wherein either the C-terminal carboxy group, the N-terminal amino group or side-chain functional group has been chemically codified to another functional group. For example, aspartic acid-(beta-methyl ester) is an amino acid analog of aspartic acid; N-ethylglycine is an amino acid analog of glycine; or alanine carboxamide is an amino acid analog of alanine.</p>
    <p num="p-0070">The term “amino acid residue” refers to radicals having the structure: (1) —C(O)—R—NH—, wherein R typically is —CH(R′)—, wherein R′ is an amino acid side chain, typically H or a carbon containing substitutent; or (2),</p>
    <p num="p-0071"> <chemistry id="CHEM-US-00001" num="00001"> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US7297761B2/US07297761-20071120-C00001.png"> <img id="EMI-C00001" he="15.58mm" wi="18.71mm" file="US07297761-20071120-C00001.TIF" alt="Figure US07297761-20071120-C00001" img-content="chem" img-format="tif" src="//patentimages.storage.googleapis.com/US7297761B2/US07297761-20071120-C00001.png" class="patent-full-image" width="74" height="62"> </a> </div> <attachments> <attachment idref="CHEM-US-00001" attachment-type="cdx" file="US07297761-20071120-C00001.CDX"> </attachment> <attachment idref="CHEM-US-00001" attachment-type="mol" file="US07297761-20071120-C00001.MOL"> </attachment> </attachments> </chemistry> <br>
wherein p is 1, 2 or 3 representing the azetidinecarboxylic acid, proline or pipecolic acid residues, respectively.
</p>
    <p num="p-0072">The term “lower” referred to herein in connection with organic radicals such as alkyl groups defines such groups with up to and including about 6, preferably up to and including 4 and advantageously one or two carbon atoms. Such groups may be straight chain or branched chain.</p>
    <p num="p-0073">“Pharmaceutically acceptable salt” includes salts of the compounds described herein derived from the combination of such compounds and an organic or inorganic acid. In practice the use of the salt form amounts to use of the base form. The compounds are useful in both free base and salt form.</p>
    <p num="p-0074">In addition, the following abbreviations stand for the following:</p>
    <p num="p-0075">“ACN” or “CH<sub>3</sub>CN” refers to acetonitrile.</p>
    <p num="p-0076">“Boc”, “tBoc” or “Tboc” refers to t-butoxy carbonyl.</p>
    <p num="p-0077">“DCC” refers to N,N′-dicyclohexylcarbodiimide.</p>
    <p num="p-0078">“Fmoc” refers to fluorenylmethoxycarbonyl.</p>
    <p num="p-0079">“HBTU” refers to 2-(1H-benzotriazol-1-yl)-1,1,3,3,-tetramethyluronium hexaflurophosphate.</p>
    <p num="p-0080">“HOBt” refers to 1-hydroxybenzotriazole monohydrate.</p>
    <p num="p-0081">“homop” or hpro” refers to homoproline.</p>
    <p num="p-0082">“MeAla” or “Nme” refers to N-methylalanine.</p>
    <p num="p-0083">“naph” refers to naphthylalanine.</p>
    <p num="p-0084">“pG” or pGly” refers to pentylglycine.</p>
    <p num="p-0085">“tBuG” refers to tertiary-butylglycine.</p>
    <p num="p-0086">“ThioP” or tPro” refers to thioproline.</p>
    <p num="p-0087">3Hyp” refers to 3-hydroxyproline</p>
    <p num="p-0088">4Hyp” refers to 4-hydroxyproline</p>
    <p num="p-0089">NAG” refers to N-alkylglycine</p>
    <p num="p-0090">NAPG” refers to N-alkylpentylglycine</p>
    <p num="p-0091">“Norval” refers to norvaline</p>
    <p num="p-0092">“Norleu” refers to norleucine</p>
    <p num="h-0009">Preparation of Compounds</p>
    <p num="p-0093">The exendins and exendin agonists described herein may be prepared using standard solid-phase peptide synthesis techniques and preferably an automated or semiautomated peptide synthesizer. Typically, using such techniques, an α-N-carbamoyl protected amino acid and an amino acid attached to the growing peptide chain on a resin are coupled at room temperature in an inert solvent such as dimethylformamide, N-methylpyrrolidinone or methylene chloride in the presence of coupling agents such as dicyclohexylcarbodiimide and 1-hydroxybenzotriazole in the presence of a base such as diisopropylethylamine. The α-N-carbamoyl protecting group is removed from the resulting peptide-resin using a reagent such as trifluoroacetic acid or piperidine, and the coupling reaction repeated with the next desired N-protected amino acid to be added to the peptide chain. Suitable N-protecting groups are well known in the art, with t-butyloxycarbonyl (tBoc) and fluorenylmethoxycarbonyl (Fmoc) being preferred herein.</p>
    <p num="p-0094">The solvents, amino acid derivatives and 4-methylbenzhydryl-amine resin used in the peptide synthesizer may be purchased from Applied Biosystems Inc. (Foster City, Calif.). The following side-chain protected amino acids may be purchased from Applied Biosystems, Inc.: Boc-Arg(Mts), Fmoc-Arg(Pmc), Boc-Thr(Bzl), Fmoc-Thr(t-Bu), Boc-Ser(Bzl), Fmoc-Ser(t-Bu), Boc-Tyr(BrZ), Fmoc-Tyr(t-Bu), Boc-Lys(Cl-Z), Fmoc-Lys(Boc), Boc-Glu(Bzl), Fmoc-Glu(t-Bu), Fmoc-His(Trt), Fmoc-Asn(Trt), and Fmoc-Gln(Trt). Boc-His(BOM) may be purchased from Applied Biosystems, Inc. or Bachem Inc. (Torrance, Calif.). Anisole, dimethylsulfide, phenol, ethanedithiol, and thioanisole may be obtained from Aldrich Chemical Company (Milwaukee, Wis.). Air Products and Chemicals (Allentown, Pa.) supplies HF. Ethyl ether, acetic acid and methanol may be purchased from Fisher Scientific (Pittsburgh, Pa.).</p>
    <p num="p-0095">Solid phase peptide synthesis may be carried out with an automatic peptide synthesizer (Model 430A, Applied Biosystems Inc., Foster City, Calif.) using the NMP/HOBt (Option 1) system and tBoc or Fmoc chemistry (see, Applied Biosystems User's Manual for the ABI 430A Peptide Synthesizer, Version 1.3B Jul. 1, 1988, section 6, pp. 49-70, Applied Biosystems, Inc., Foster City, Calif.) with capping. Boc-peptide-resins may be cleaved with HF (−5° C. to 0° C., 1 hour). The peptide may be extracted from the resin with alternating water and acetic acid, and the filtrates lyophilized. The Fmoc-peptide resins may be cleaved according to standard methods (<i>Introduction to Cleavage Techniques</i>, Applied Biosystems, Inc., 1990, pp. 6-12). Peptides may be also be assembled using an Advanced Chem Tech Synthesizer (Model MPS 350,. Louisville, Ky.).</p>
    <p num="p-0096">Peptides may be purified by RP-HPLC (preparative and analytical) using a Waters Delta Prep 3000 system. A C4, C8 or C18 preparative column (10μ, 2.2×25 cm; Vydac, Hesperia, Calif.) may be used to isolate peptides, and purity may be determined using a C4, C8 or C18 analytical column (5μ, 0.46×25 cm; Vydac). Solvents (A=0.1% TFA/water and B=0.1% TFA/CH<sub>3</sub>CN) may be delivered to the analytical column at a flowrate of 1.0 ml/min and to the preparative column at 15 ml/min. Amino acid analyses may be performed on the Waters Pico Tag system and processed using the Maxima program. Peptides may be hydrolyzed by vapor-phase acid hydrolysis (115° C., 20-24 h). Hydrolysates may be derivatized and analyzed by standard methods (Cohen, et al., <i>The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis</i>, pp. 11-52, Millipore Corporation, Milford, Mass. (1989)). Fast atom bombardment analysis may be carried out by M-Scan, Incorporated (West Chester, Pa.). Mass calibration may be performed using cesium iodide or cesium iodide/glycerol. Plasma desorption ionization analysis using time of flight detection may be carried out on an Applied Biosystems Bio-Ion 20 mass spectrometer. Electrospray mass spectroscopy may be carried out on a VG-Trio machine.</p>
    <p num="p-0097">Peptide compounds useful in the invention may also be prepared using recombinant DNA techniques, using methods now known in the art. See, e.g., Sambrook et al., <i>Molecular Cloning: A Laboratory Manual, </i>2d Ed., Cold Spring Harbor (1989). Non-peptide compounds useful in the present invention may be prepared by art-known methods. For example, phosphate-containing amino acids and peptides containing such amino acids, may be prepared using methods known in the art. See. e.g., Bartlett and Landen, <i>Biorg. Chem. </i>14:356-377 (1986).</p>
    <p num="p-0098">The compounds described above are useful in view of their pharmacological properties. In particular, the compounds of the invention possess activity as agents to reduce food intake. They can be used to treat conditions or diseases which can be alleviated by reducing food intake.</p>
    <p num="p-0099">Compositions useful in the invention may conveniently be provided in the form of formulations suitable for parenteral (including intravenous, intramuscular and subcutaneous) or nasal or oral administration. In some cases, it will be convenient to provide an exendin or exendin agonist and another food-intake-reducing, plasma glucose-lowering or plasma lipid-lowering agent, such as amylin, an amylin agonist, a CCK, or a leptin, in a single composition or solution for administration together. In other cases, it may be more advantageous to administer the additional agent separately from said exendin or exendin agonist. A suitable administration format may best be determined by a medical practitioner for each patient individually. Suitable pharmaceutically acceptable carriers and their formulation are described in standard formulation treatises, e.g., <i>Remington's Pharmaceutical Sciences </i>by E. W. Martin. See also Wang, Y. J. and Hanson, M. A. “Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers,” <i>Journal of Parenteral Science and Technology</i>, Technical Report No. 10, Supp. 42:2S (1988).</p>
    <p num="p-0100">Compounds useful in the invention can be provided as parenteral compositions for injection or infusion. They can, for example, be suspended in an inert oil, suitably a vegetable oil such as sesame, peanut, olive oil, or other acceptable carrier. Preferably, they are suspended in an aqueous carrier, for example, in an isotonic buffer solution at a pH of about 3.0 to 8.0, preferably at a pH of about 3.5 to 5.0. These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH buffering agents. Useful buffers include for example, sodium acetate/acetic acid buffers. A form of repository or “depot” slow release preparation may be used so that therapeutically effective amounts of the preparation are delivered into the bloodstream over many hours or days following transdermal injection or delivery.</p>
    <p num="p-0101">The desired isotonicity may be accomplished using sodium chloride or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol, polyols (such as mannitol and sorbitol), or other inorganic or organic solutes. Sodium chloride is preferred particularly for buffers containing sodium ions.</p>
    <p num="p-0102">The claimed compositions can also be formulated as pharmaceutically acceptable salts (e.g., acid addition salts) and/or complexes thereof. Pharmaceutically acceptable salts are non-toxic salts at the concentration at which they are administered. The preparation of such salts can facilitate the pharmacological use by altering the physical-chemical characteristics of the composition without preventing the composition from exerting its physiological effect. Examples of useful alterations in physical properties include lowering the melting point to facilitate transmucosal administration and increasing the solubility to facilitate the administration of higher concentrations of the drug.</p>
    <p num="p-0103">Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate. Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, and quinic acid. Such salts may be prepared by, for example, reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the ions of an existing salt for another ion on a suitable ion exchange resin.</p>
    <p num="p-0104">Carriers or excipients can also be used to facilitate administration of the compound. Examples of carriers and excipients include calcium carbonate, calcium phosphate, various sugars such as lactose, glucose, or sucrose, or types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents. The compositions or pharmaceutical composition can be administered by different routes including intravenously, intraperitoneal, subcutaneous, and intramuscular, orally, topically, transmucosally, or by pulmonary inhalation.</p>
    <p num="p-0105">If desired, solutions of the above compositions may be thickened with a thickening agent such as methyl cellulose. They may be prepared in emulsified form, either water in oil or oil in water. Any of a wide variety of pharmaceutically acceptable emulsifying agents may be employed including, for example, acacia powder, a non-ionic surfactant (such as a Tween), or an ionic surfactant (such as alkali polyether alcohol sulfates or sulfonates, e.g., a Triton).</p>
    <p num="p-0106">Compositions useful in the invention are prepared by mixing the ingredients following generally accepted procedures. For example, the selected components may be simply mixed in a blender or other standard device to produce a concentrated mixture which may then be adjusted to the final concentration and viscosity by the addition of water or thickening agent and possibly a buffer to control pH or an additional solute to control tonicity.</p>
    <p num="p-0107">For use by the physician, the compositions will be provided in dosage unit form containing an amount of an exendin or exendin agonist, for example, exendin-3, and/or exendin-4, with or without another food intake-reducing, plasma glucose-lowering or plasma lipid-lowering agent. Therapeutically effective amounts of an exendin or exendin agonist for use in reducing food intake are those that suppress appetite at a desired level. As will be recognized by those in the field, an effective amount of therapeutic agent will vary with many factors including the age and weight of the patient, the patient's physical condition, the blood sugar level and other factors.</p>
    <p num="p-0108">The effective daily appetite-suppressing dose of the compounds will typically be in the range of about 10 to 30 μg to about 5 mg/day, preferably about 10 to 30 μg to about 2 mg/day and more preferably about 10 to 100 μg to about 1 mg/day, most preferably about 30 μg to about 500 μg/day, for a 70 kg patient, administered in a single or divided doses. The exact dose to be administered is determined by the attending clinician and is dependent upon where the particular compound lies within the above quoted range, as well as upon the age, weight and condition of the individual. Administration should begin whenever the suppression of food intake, or weight lowering is desired, for example, at the first sign of symptoms or shortly after diagnosis of obesity, diabetes mellitus, or insulin-resistance syndrome. Administration may be by injection, preferably subcutaneous or intramuscular orally active compounds may be taken orally, however dosages should be increased 5-10 fold.</p>
    <p num="p-0109">The optimal formulation and mode of administration of compounds of the present application to a patient depend on factors known in the art such as the particular disease or disorder, the desired effect, and the type of patient. While the compounds will typically be used to treat human subjects they may also be used to treat similar or identical diseases in other vertebrates such as other primates, farm animals such as swine, cattle and poultry, and sports animals and pets such as horses, dogs and cats.</p>
    <p num="p-0110">To assist in understanding the present invention, the following Examples are included. The experiments relating to this invention should not, of course, be construed as specifically limiting the invention and such variations of the invention, now known or later developed, which would be within the purview of one skilled in the art are considered to fall within the scope of the invention as described herein and hereinafter claimed.</p>
    <heading>EXAMPLE 1</heading> <heading>Exendin Injections Reduced the Food Intake of Normal Mice</heading> <p num="p-0111">All mice (NIH:Swiss mice) were housed in a stable environment of 22 (±2)° C., 60 (±10) % humidity and a 12:12 light:dark cycle; with lights on at 0600. Mice were housed in groups of four in standard cages with ad libitum access to food (Teklad: LM 485; Madison, Wis.) and water except as noted, for at least two weeks before the experiments.</p>
    <p num="p-0112">All experiments were conducted between the hours of 0700 and.0900. The mice were food deprived (food removed at 1600 hr from all animals on day prior to experiment) and individually housed. All mice received an intraperitoneal injection (5 μl/kg) of either saline or exendin-4 at doses of 0.1, 1.0, 10 and 100 μg/kg and were immediately presented with a pre-weighed food pellet (Teklad LM 485). The food pellet was weighed at 30-minute, 1-hr, 2-hr and 6-hr intervals to determine the amount of food eaten.</p>
    <p num="p-0113"> <figref idrefs="DRAWINGS">FIG. 1</figref> depicts cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline, 2 doses of GLP-1, or 4 doses of exendin-4. At doses up to 100 μg/kg, GLP-1 had no effect on food intake measured over any period, a result consistent with that previously reported (Bhavsar, S. P., et al., <i>Soc. Neurosci. Abstr. </i>21:460 (188.8) (1995); and Turton, M. D., <i>Nature, </i>379:69-72, (1996)).</p>
    <p num="p-0114">In contrast, exendin-4 injections potently and dose-dependently inhibited food intake. The ED<sub>50 </sub>for inhibition of food intake over 30 min was 1 μg/kg, which is a level about as potent as amylin (ED<sub>50 </sub>3.6 μg/kg) or the prototypical peripheral satiety agent, CCK (ED<sub>50 </sub>0.97 μg/kg) as measured in this preparation. However, in contrast to the effects of amylin or CCK, which abate after 1-2 hours, the inhibition of food intake with exendin-4 was still present after at least 6 hours after injection.</p>
    <heading>EXAMPLE 2</heading> <heading>Exendin Reduced the Food Intake of Obese Mice</heading> <p num="p-0115">All mice (female ob/ob mice) were housed in a stable environment of 22 (±2)° C., 60 (±10) % humidity and a 12:12 light:dark cycle; with lights on at 0600. Mice were housed in groups of four in standard cages with ad libitum access to food (Teklad: LM 485) and water except as noted, for at least two weeks before the experiments.</p>
    <p num="p-0116">All experiments were conducted between the hours of 0700 and 0900. The mice were food deprived (food removed at 1600 hr from all animals on day prior to experiment) and individually housed. All mice received an intraperitoneal injection (5 μl/kg) of either saline or exendin-4 at doses of 0.1, 1.0 and 10 μg/kg (female ob/ob mice) and were immediately presented with a pre-weighed food pellet (Teklad LM 485). The food pellet was weighed at 30-minute, 1-hr, 2-hr and 6-hr intervals to determine the amount of food eaten.</p>
    <p num="p-0117"> <figref idrefs="DRAWINGS">FIG. 2</figref> depicts the effect of exendin-4 in the ob/ob mouse model of obesity. The obese mice had a similar food intake-related response to exendin as the normal mice. Moreover, the obese mice were not hypersensitive to exendin, as has been observed with amylin and leptin (Young, A. A., et al., <i>Program and Abstracts, </i>10th International Congress of Endocrinology, Jun. 12-15, 1996 San Francisco, pg 419 (P2-58)).</p>
    <heading>EXAMPLE 3</heading> <heading>Intracerebroventricular Injections of Exendin Inhibited Food Intake in Rats</heading> <p num="p-0118">All rats (Harlan Sprague-Dawley) were housed in a stable environment of 22 (±2)° C., 60 (±10) % humidity and a 12:12 light:dark cycle; with lights on at 0600. Rats were obtained from Zivic Miller with an intracerebroventricular cannula (ICV cannula) implanted (coordinates determined by actual weight of animals and referenced to Paxinos, G. and Watson, C. “The Rat Brain in stereotaxic coordinates,” second edition. Academic Press) and were individually housed in standard cages with ad libitum access to food (Teklad: LM 485) and water for at least one week before the experiments.</p>
    <p num="p-0119">All injections were given between the hours of 1700 and 1800. The rats were habituated to the ICV injection procedure at least once before the ICV administration of compound. All rats received an ICV injection (2 μl/30 seconds) of either saline or exendin-4 at doses of 0.01, 0.03, 0.1, 0.3, and 1.0 μg. All animals were then presented with pre-weighed food (Teklad LM 485) at 1800, when the lights were turned off. The amount of food left was weighed at 2-hr, 12-hr and 24-hr intervals to determine the amount of food eaten by each animal.</p>
    <p num="p-0120"> <figref idrefs="DRAWINGS">FIG. 3</figref> depicts a dose-dependent inhibition of food intake in rats that received doses greater than 0.1 μg/rat. The ED<sub>50 </sub>was≈0.1 μg, exendin-4 is thus≈100-fold more potent than intracerebroventricular injections of GLP-1 as reported by Turton, M. D., et al. (<i>Nature </i>379:69-72 (1996)).</p>
    <heading>EXAMPLE 4</heading> <heading>Exendin Agonists Reduced the Food Intake in</heading> <heading>Mice</heading> <p num="p-0121">All mice (NIH:Swiss mice) were housed in a stable environment of 22 (±2)° C., 60 (±10) % humidity and a 12:12 light:dark cycle; with lights on at 0600. Mice were housed in groups of four in standard cages with ad libitum access to food (Teklad: LM 485; Madison, Wis.) and water except as noted, for at least two weeks before the experiments.</p>
    <p num="p-0122">All experiments were conducted between the hours of 0700 and 0900. The mice were food deprived (food removed at 1600 hr from all animals on day prior to experiment) and individually housed. All mice received an intraperitoneal injection (5 μl/kg) of either saline or test compound at doses of 1, 10, and 100 μg/kg and immediately presented with a food pellet (Teklad LM 485). The food pellet was weighed at 30-minute, 1-hr, 2-hr and 6-hr intervals to determine the amount of food eaten.</p>
    <p num="p-0123"> <figref idrefs="DRAWINGS">FIG. 4</figref> depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection-of saline or exendin-4 (1-30) (“Compound 1”) in doses of 1, 10 and 100 μg/kg.</p>
    <p num="p-0124"> <figref idrefs="DRAWINGS">FIG. 5</figref> depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline or exendin-4 (1-30) amide (“Compound 2”) in doses of 1, 10 and 100 μg/kg.</p>
    <p num="p-0125"> <figref idrefs="DRAWINGS">FIG. 6</figref> depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline or exendin-4 (1-28) amide (“Compound 3”) in doses of 1, 10 and 100 μg/kg.</p>
    <p num="p-0126"> <figref idrefs="DRAWINGS">FIG. 7</figref> depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline or <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4 amide (“Compound 4”) in doses of 1, 10 and 100 μg/kg.</p>
    <p num="p-0127"> <figref idrefs="DRAWINGS">FIG. 8</figref> depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline or <sup>14</sup>Leu,<sup>25</sup>Phe exendin-4 (1-28) amide (“Compound 5”) in doses of 1, 10 and 100 μg/kg.</p>
    <p num="p-0128"> <figref idrefs="DRAWINGS">FIG. 9</figref> depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH:Swiss mice following ip injection of saline or <sup>14</sup>Leu,<sup>22</sup>Ala,<sup>25</sup>Phe exendin-4 (1-28) amide (“Compound 6”) in doses of 1, 10 and 100 μg/kg.</p>
    <heading>EXAMPLE 5</heading> <heading>Preparation of Amidated Peptide Having SEQ. ID. NO. 9</heading> <p num="p-0129">The above-identified peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.). In general, single-coupling cycles were used throughout the synthesis and Fast Moc (HBTU activation) chemistry was employed. However, at some positions coupling was less efficient than expected and double couplings were required. In particular, residues Asp<sub>9</sub>, Thr<sub>7 </sub>and Phe<sub>6 </sub>all required double coupling. Deprotection (Fmoc group removal)of the growing peptide chain using piperidine was not always efficient. Double deprotection was required at positions Arg<sub>20</sub>, Val<sub>19 </sub>and Leu<sub>14</sub>. Final deprotection of the completed peptide resin was achieved using a mixture of triethylsilane (0.2 mL), ethanedithiol (0.2 mL), anisole (0.2 mL), water (0.2 mL) and trifluoroacetic acid (15 mL) according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc.) The peptide was precipitated in ether/water (50 mL) and centrifuged. The precipitate was reconstituted in glacial acetic acid and lyophilized. The lyophilized peptide was dissolved in water). Crude purity was about 55%.</p>
    <p num="p-0130">Used in purification steps and analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).</p>
    <p num="p-0131">The solution containing peptide was applied to a preparative C-18 column and purified (10% to 40% Solvent B in Solvent A over 40 minutes). Purity of fractions was determined isocratically using a C-18 analytical column. Pure fractions were pooled furnishing the above-identified peptide. Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.5 minutes. Electrospray Mass Spectrometry (M): calculated 4131.7; found 4129.3.</p>
    <heading>EXAMPLE 6</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 10</heading> <p num="p-0132">The above-identified peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 25% to 75% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 21.5 minutes. Electrospray Mass Spectrometry (M): calculated 4168.6; found 4171.2.</p>
    <heading>EXAMPLE 7</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 11</heading> <p num="p-0133">The above-identified peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 17.9 minutes. Electrospray Mass Spectrometry (M): calculated 4147.6; found 4150.2.</p>
    <heading>EXAMPLE 8</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 12</heading> <p num="p-0134">The above-identified peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 35% to 65% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 19.7 minutes. Electrospray Mass Spectrometry (M): calculated 4212.6; found 4213.2.</p>
    <heading>EXAMPLE 9</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 13</heading> <p num="p-0135">The above-identified peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 50% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 16.3 minutes. Electrospray Mass Spectrometry (M): calculated 4262.7; found 4262.4.</p>
    <heading>EXAMPLE 10</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 14</heading> <p num="p-0136">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4172.6</p>
    <heading>EXAMPLE 11</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 15</heading> <p num="p-0137">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl-phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4224.7.</p>
    <heading>EXAMPLE 12</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 16</heading> <p num="p-0138">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4172.6</p>
    <heading>EXAMPLE 13</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 17</heading> <p num="p-0139">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4186.6</p>
    <heading>EXAMPLE 14</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 18</heading> <p num="p-0140">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4200.7</p>
    <heading>EXAMPLE 15</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 19</heading> <p num="p-0141">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4200.7</p>
    <heading>EXAMPLE 16</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 20</heading> <p num="p-0142">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4202.7.</p>
    <heading>EXAMPLE 17</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 21</heading> <p num="p-0143">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4145.6.</p>
    <heading>EXAMPLE 18</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 22</heading> <p num="p-0144">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4184.6.</p>
    <heading>EXAMPLE 19</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 23</heading> <p num="p-0145">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4145.6.</p>
    <heading>EXAMPLE 20</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 24</heading> <p num="p-0146">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4224.7.</p>
    <heading>EXAMPLE 21</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 25</heading> <p num="p-0147">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4172.6.</p>
    <heading>EXAMPLE 22</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 26</heading> <p num="p-0148">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4115.5.</p>
    <heading>EXAMPLE 23</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 27</heading> <p num="p-0149">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4188.6.</p>
    <heading>EXAMPLE 24</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 28</heading> <p num="p-0150">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4131.6.</p>
    <heading>EXAMPLE 25</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 29</heading> <p num="p-0151">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4172.6.</p>
    <heading>EXAMPLE 26</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 30</heading> <p num="p-0152">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4145.6.</p>
    <heading>EXAMPLE 27</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 31</heading> <p num="p-0153">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the thioproline positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4266.8.</p>
    <heading>EXAMPLE 28</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 32</heading> <p num="p-0154">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the thioproline positions 38, 37 and 36. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4246.8.</p>
    <heading>EXAMPLE 29</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 33</heading> <p num="p-0155">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the homoproline positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4250.8.</p>
    <heading>EXAMPLE 30</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 34</heading> <p num="p-0156">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the homoproline positions 38, 37, and 36. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4234.8.</p>
    <heading>EXAMPLE 31</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 35</heading> <p num="p-0157">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the thioproline positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4209.8.</p>
    <heading>EXAMPLE 32</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 36</heading> <p num="p-0158">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the homoproline positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4193.7.</p>
    <heading>EXAMPLE 33</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 37</heading> <p num="p-0159">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the N-methylalanine positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3858.2.</p>
    <heading>EXAMPLE 34</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 38</heading> <p num="p-0160">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the N-methylalanine positions 38, 37 and 36. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3940.3.</p>
    <heading>EXAMPLE 35</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 39</heading> <p num="p-0161">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the N-methylalanine positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3801.1.</p>
    <heading>EXAMPLE 36</heading> <heading>Preparation of C-terminal Carboxylic Acid Peptides Corresponding to the above C-terminal Amide Sequences</heading> <p num="p-0162">The above peptides of Examples 5 to 35 are assembled on the so called Wang resin (p-alkoxybenzylalacohol resin (Bachem, 0.54 mmole/g)) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry provides an experimentally determined (M).</p>
    <heading>EXAMPLE 37</heading> <heading>Preparation of Peptide Having SEQ. ID. NO. 7</heading> <p num="p-0163">
      <tables id="TABLE-US-00004" num="00004"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="147pt" align="left"> </colspec> <colspec colname="2" colwidth="70pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp</td>
                <td class="description-td">[SEQ. ID. NO. 7]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Leu Ser Lys Gln Met Glu Glu Glu Ala</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Val Arg Leu Phe Ile Glu Trp Leu Lys</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asn Gly Gly-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0164">The above amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.). In general, single-coupling cycles were used throughout the synthesis and Fast Moc (HBTU activation) chemistry was employed. Deprotection (Fmoc group removal)of the growing peptide chain was achieved using piperidine. Final deprotection of the completed peptide resin was achieved using a mixture of triethylsilane (0.2 mL), ethanedithiol (0.2 mL), anisole (0.2 mL), water (0.2 mL) and trifluoroacetic acid (15 mL) according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc.) The peptide was precipitated in ether/water (50 mL) and centrifuged. The precipitate was reconstituted in glacial acetic acid and lyophilized. The lyophilized peptide was dissolved in water). Crude purity was about 75%.</p>
    <p num="p-0165">Used in purification steps and analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). The solution containing peptide was applied to a preparative C-18 column and purified (10% to 40% Solvent B in Solvent A over 40 minutes). Purity of fractions was determined isocratically using a C-18 analytical column. Pure fractions were pooled furnishing the above-identified peptide. Analytical RP-HPLC (gradient 30% to 50% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 18.9 minutes. Electrospray Mass Spectrometry (M): calculated 3408.0; found 3408.9.</p>
    <heading>EXAMPLE 38</heading> <p num="p-0166">Preparation of Peptide Having SEQ ID NO. 40</p>
    <p num="p-0167">
      <tables id="TABLE-US-00005" num="00005"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 40]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0168">The above amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 40% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 17.9 minutes. Electrospray Mass Spectrometry (M): calculated 3294.7; found 3294.8.</p>
    <heading>EXAMPLE 39</heading> <heading>Preparation of Peptide Having SEQ ID NO. 41</heading> <p num="p-0169">
      <tables id="TABLE-US-00006" num="00006"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 41]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0170">The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 29% to 36% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 20.7 minutes. Electrospray Mass Spectrometry (M): calculated 3237.6; found 3240.</p>
    <heading>EXAMPLE 40</heading> <heading>Preparation of Peptide Having SEQ ID NO. 42</heading> <p num="p-0171">
      <tables id="TABLE-US-00007" num="00007"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Ala Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 42]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0172">The above amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 15.2 minutes. Electrospray Mass Spectrometry (M): calculated 3251.6; found 3251.5.</p>
    <heading>EXAMPLE 41</heading> <heading>Preparation of Peptide Having SEQ ID NO. 43</heading> <p num="p-0173">
      <tables id="TABLE-US-00008" num="00008"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Ala Phe Thr</td>
                <td class="description-td">[SEQ. ID. NO. 43]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Asp Leu Ser Lys Gln Leu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Glu Ala Val Arg Leu Phe Ile</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0174">The above amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 13.1 minutes. Electrospray Mass Spectrometry (M): calculated 3207.6; found 3208.3.</p>
    <heading>EXAMPLE 42</heading> <heading>Preparation of Peptide Having SEQ ID NO. 44</heading> <p num="p-0175">
      <tables id="TABLE-US-00009" num="00009"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Ala Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 44]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0176">The above amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 35% to 45% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 12.8 minutes. Electrospray Mass Spectrometry (M): calculated 3161.5; found 3163.</p>
    <heading>EXAMPLE 43</heading> <heading>Preparation of Peptide Having SEQ ID NO. 45</heading> <p num="p-0177">
      <tables id="TABLE-US-00010" num="00010"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ala</td>
                <td class="description-td">[SEQ. ID. NO. 45]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0178">The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 15.2 minutes. Electrospray Mass Spectrometry (M): calculated 3221.6; found 3222.7.</p>
    <heading>EXAMPLE 44</heading> <heading>Preparation of Peptide Having SEQ ID NO. 46</heading> <p num="p-0179">
      <tables id="TABLE-US-00011" num="00011"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 46]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0180">The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 34% to 44% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.3 minutes. Electrospray Mass Spectrometry (M): calculated 3195.5; found 3199.4.</p>
    <heading>EXAMPLE 45</heading> <heading>Preparation of Peptide Having SEQ ID NO. 47</heading> <p num="p-0181">
      <tables id="TABLE-US-00012" num="00012"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 47]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ala Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0182">The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 15.7 minutes. Electrospray Mass Spectrometry (M): calculated 3221.6; found 3221.6.</p>
    <heading>EXAMPLE 46</heading> <heading>Preparation of Peptide having SEQ ID NO. 48</heading> <p num="p-0183">
      <tables id="TABLE-US-00013" num="00013"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 48]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Ala</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0184">The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 18.1 minutes. Electrospray Mass Spectrometry (M): calculated 3180.5; found 3180.9.</p>
    <heading>EXAMPLE 47</heading> <heading>Preparation of Peptide Having SEQ ID NO. 49</heading> <p num="p-0185">
      <tables id="TABLE-US-00014" num="00014"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 49]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ala Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0186">The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Compound 1. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 17.0 minutes. Electrospray Mass Spectrometry (M): calculated 3180.6; found 3182.8.</p>
    <heading>EXAMPLE 48</heading> <heading>Preparation of Peptide Having SEQ ID NO. 50</heading> <p num="p-0187">
      <tables id="TABLE-US-00015" num="00015"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 50]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Ala Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0188">The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 32% to 42% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.9 minutes. Electrospray Mass Spectrometry (M): calculated 3195.5; found 3195.9.</p>
    <heading>EXAMPLE 49</heading> <heading>Preparation of Peptide Having SEQ ID NO. 51</heading> <p num="p-0189">
      <tables id="TABLE-US-00016" num="00016"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 51]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Leu Ala Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0190">The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 37% to 47% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 17.9 minutes. Electrospray Mass Spectrometry (M): calculated 3179.6; found 3179.0.</p>
    <heading>EXAMPLE 50</heading> <heading>Preparation of Peptide Having SEQ ID NO. 52</heading> <p num="p-0191">
      <tables id="TABLE-US-00017" num="00017"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 52]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Leu Glu Ala Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0192">The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 37% to 47% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.3 minutes. Electrospray Mass Spectrometry (M): calculated 3179.6; found 3180.0.</p>
    <heading>EXAMPLE 51</heading> <heading>Preparation of Peptide Having SEQ ID NO. 53</heading> <p num="p-0193">
      <tables id="TABLE-US-00018" num="00018"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 53]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Leu Glu Glu Ala Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0194">The above-identified peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 37% to .47% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 13.7 minutes. Electrospray Mass Spectrometry (M): calculated 3179.6; found 3179.0.</p>
    <heading>EXAMPLE 52</heading> <heading>Preparation of Peptide Having SEQ ID NO. 54</heading> <p num="p-0195">
      <tables id="TABLE-US-00019" num="00019"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 54]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Leu Glu Glu Glu Ala Ala Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0196">The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 35% to 45% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.0 minutes. Electrospray Mass Spectrometry (M): calculated 3209.6; found 3212.8.</p>
    <heading>EXAMPLE 53</heading> <heading>Preparation of Peptide Having SEQ ID NO. 55</heading> <p num="p-0197">
      <tables id="TABLE-US-00020" num="00020"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 55]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Leu Glu Glu Glu Ala Val Ala Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0198">The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.3 minutes. Electrospray Mass Spectrometry (M): calculated 3152.5; found 3153.5.</p>
    <heading>EXAMPLE 54</heading> <heading>Preparation of Peptide Having SEQ ID NO. 56</heading> <p num="p-0199">
      <tables id="TABLE-US-00021" num="00021"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 56]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Ala Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0200">The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 35% to 45% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 12.1 minutes. Electrospray Mass Spectrometry (M): calculated 3195.5; found 3197.7.</p>
    <heading>EXAMPLE 55</heading> <heading>Preparation of Peptide Having SEQ ID NO. 57</heading> <p num="p-0201">
      <tables id="TABLE-US-00022" num="00022"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 57]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Ala</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0202">The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 10.9 minutes. Electrospray Mass Spectrometry (M): calculated 3179.6; found 3180.5.</p>
    <heading>EXAMPLE 56</heading> <heading>Preparation of Peptide Having SEQ ID NO. 58</heading> <p num="p-0203">
      <tables id="TABLE-US-00023" num="00023"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 58]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ala Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0204">The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 32% to 42% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 17.5 minutes. Electrospray Mass Spectrometry (M): calculated 3161.5; found 3163.0.</p>
    <heading>EXAMPLE 57</heading> <heading>Preparation of Peptide Having SEQ ID NO. 59</heading> <p num="p-0205">
      <tables id="TABLE-US-00024" num="00024"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 59]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Ala Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0206">The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 32% to 42% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 19.5 minutes. Electrospray Mass Spectrometry (M): calculated 3195.5; found 3199.</p>
    <heading>EXAMPLE 58</heading> <heading>Preparation of Peptide Having SEQ ID NO. 60</heading> <p num="p-0207">
      <tables id="TABLE-US-00025" num="00025"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 60]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Ala Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0208">The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.5 minutes. Electrospray Mass Spectrometry (M): calculated 3180.5; found 3183.7.</p>
    <heading>EXAMPLE 59</heading> <heading>Preparation of Peptide Having SEQ ID NO. 61</heading> <p num="p-0209">
      <tables id="TABLE-US-00026" num="00026"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 61]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Ala-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0210">The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 34% to 44% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 22.8 minutes. Electrospray Mass Spectrometry (M): calculated 3194.6; found 3197.6.</p>
    <heading>EXAMPLE 60</heading> <heading>Preparation of Peptide Having SEQ ID NO. 62</heading> <p num="p-0211">
      <tables id="TABLE-US-00027" num="00027"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 62]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala Pro Pro Pro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0212">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4099.6.</p>
    <heading>EXAMPLE 61</heading> <heading>Preparation of Peptide Having SEQ ID NO. 63</heading> <p num="p-0213">
      <tables id="TABLE-US-00028" num="00028"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 63]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala Pro Pro Pro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0214">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4042.5.</p>
    <heading>EXAMPLE 62</heading> <heading>Preparation of Peptide Having SEQ ID NO. 64</heading> <p num="p-0215">
      <tables id="TABLE-US-00029" num="00029"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 64]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala Pro Pro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0216">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4002.4</p>
    <heading>EXAMPLE 63</heading> <heading>Preparation of Peptide Having SEQ ID NO. 65</heading> <p num="p-0217">
      <tables id="TABLE-US-00030" num="00030"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 65]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala Pro Pro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0218">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3945.4.</p>
    <heading>EXAMPLE 64</heading> <heading>Preparation of Peptide Having SEQ ID NO. 66</heading> <p num="p-0219">
      <tables id="TABLE-US-00031" num="00031"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 66]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala Pro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0220">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3905.3.</p>
    <heading>EXAMPLE 65</heading> <heading>Preparation of Peptide Having SEQ ID NO. 67</heading> <p num="p-0221">
      <tables id="TABLE-US-00032" num="00032"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 67]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala Pro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0222">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3848.2.</p>
    <heading>EXAMPLE 66</heading> <heading>Preparation of Peptide Having SEQ ID NO. 68</heading> <p num="p-0223">
      <tables id="TABLE-US-00033" num="00033"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 68]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0224">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3808.2.</p>
    <heading>EXAMPLE 67</heading> <heading>Preparation of Peptide Having SEQ ID NO. 69</heading> <p num="p-0225">
      <tables id="TABLE-US-00034" num="00034"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 69]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0226">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3751.1.</p>
    <heading>EXAMPLE 68</heading> <heading>Preparation of Peptide Having SEQ ID NO. 70</heading> <p num="p-0227">
      <tables id="TABLE-US-00035" num="00035"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 70]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0228">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3737.1.</p>
    <heading>EXAMPLE 69</heading> <heading>Preparation of Peptide Having SEQ ID NO. 71</heading> <p num="p-0229">
      <tables id="TABLE-US-00036" num="00036"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 71]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0230">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3680.1.</p>
    <heading>EXAMPLE 70</heading> <heading>Preparation of Peptide Having SEQ ID NO. 72</heading> <p num="p-0231">
      <tables id="TABLE-US-00037" num="00037"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 72]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0232">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3680.1</p>
    <heading>EXAMPLE 71</heading> <heading>Preparation of Peptide Having SEQ ID NO. 73</heading> <p num="p-0233">
      <tables id="TABLE-US-00038" num="00038"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 73]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0234">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3623.0.</p>
    <heading>EXAMPLE 72</heading> <heading>Preparation of Peptide Having SEQ ID NO. 74</heading> <p num="p-0235">
      <tables id="TABLE-US-00039" num="00039"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 74]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro Ser-</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0236">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3593.0</p>
    <heading>EXAMPLE 73</heading> <heading>Preparation of Peptide Having SEQ ID NO. 75</heading> <p num="p-0237">
      <tables id="TABLE-US-00040" num="00040"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 75]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn Gly Gly Pro Ser-</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0238">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3535.9</p>
    <heading>EXAMPLE 74</heading> <heading>Preparation of Peptide Having SEQ ID NO. 76</heading> <p num="p-0239">
      <tables id="TABLE-US-00041" num="00041"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 76]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0240">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3505.9.</p>
    <heading>EXAMPLE 75</heading> <heading>Preparation of Peptide Having SEQ ID NO. 77</heading> <p num="p-0241">
      <tables id="TABLE-US-00042" num="00042"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 77]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn Gly Gly Pro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0242">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3448.8.</p>
    <heading>EXAMPLE 76</heading> <heading>Preparation of Peptide Having SEQ ID NO. 78</heading> <p num="p-0243">
      <tables id="TABLE-US-00043" num="00043"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 78]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn Gly Gly-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0244">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3351.7.</p>
    <heading>EXAMPLE 77</heading> <heading>Preparation of Peptide Having SEQ ID NO. 79</heading> <p num="p-0245">
      <tables id="TABLE-US-00044" num="00044"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 79]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0246">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3351.8.</p>
    <heading>EXAMPLE 78</heading> <heading>Preparation of Peptide Having SEQ ID NO. 80</heading> <p num="p-0247">
      <tables id="TABLE-US-00045" num="00045"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 80]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn Gly-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0248">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3294.7.</p>
    <heading>EXAMPLE 79</heading> <heading>Preparation of Peptide Having SEQ ID NO. 81</heading> <p num="p-0249">
      <tables id="TABLE-US-00046" num="00046"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 81]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly tPro Ser Ser Gly Ala tPro</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">tPro tPro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0250">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Double couplings are required at residues 37,36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4197.1.</p>
    <heading>EXAMPLE 80</heading> <heading>Preparation of Peptide Having SEQ ID NO. 82</heading> <p num="p-0251">
      <tables id="TABLE-US-00047" num="00047"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 82]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala tPro</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">tPro tPro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0252">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Double couplings are required at residues 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4179.1.</p>
    <heading>EXAMPLE 81</heading> <heading>Preparation of Peptide Having SEQ ID NO. 83</heading> <p num="p-0253">
      <tables id="TABLE-US-00048" num="00048"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 83]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly NMeala Ser Ser Gly Ala</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Pro Pro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0254">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Double couplings are required at residues 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3948.3.</p>
    <heading>EXAMPLE 82</heading> <heading>Preparation of Peptide Having SEQ ID NO. 84</heading> <p num="p-0255">
      <tables id="TABLE-US-00049" num="00049"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 84]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly NMeala Ser Ser Gly Ala</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">NMeala Nmeala-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0256">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Double couplings are required at residues 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3840.1.</p>
    <heading>EXAMPLE 83</heading> <heading>Preparation of Peptide Having SEQ ID NO. 85</heading> <p num="p-0257">
      <tables id="TABLE-US-00050" num="00050"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 85]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly hPro Ser Ser Gly Ala hPro</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">hPro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0258">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Double couplings are required at residues 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4050.1.</p>
    <heading>EXAMPLE 84</heading> <heading>Preparation of Peptide Having SEQ ID NO. 86</heading> <p num="p-0259">
      <tables id="TABLE-US-00051" num="00051"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 86]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly hPro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala hPro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0260">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. A double coupling is required at residue 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3937.1</p>
    <heading>EXAMPLE 85</heading> <heading>Preparation of Peptide Having SEQ ID NO. 87</heading> <p num="p-0261">
      <tables id="TABLE-US-00052" num="00052"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Arg Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 87]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0262">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3827.2.</p>
    <heading>EXAMPLE 86</heading> <heading>Preparation of Peptide Having SEQ ID NO. 88</heading> <p num="p-0263">
      <tables id="TABLE-US-00053" num="00053"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 88]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0264">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes). of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3394.8.</p>
    <heading>EXAMPLE 87</heading> <heading>Preparation of Peptide Having SEQ ID NO. 89</heading> <p num="p-0265">
      <tables id="TABLE-US-00054" num="00054"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Naphthylala</td>
                <td class="description-td">[SEQ. ID. NO. 89]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Thr Ser Asp Leu Ser Lys Gln Leu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Glu Glu Ala Val Arg Leu Phe</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0266">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3289.5.</p>
    <heading>EXAMPLE 88</heading> <heading>Preparation of Peptide Having SEQ ID NO. 90</heading> <p num="p-0267">
      <tables id="TABLE-US-00055" num="00055"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Ser Ser</td>
                <td class="description-td">[SEQ. ID. NO. 90]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0268">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3280.7.</p>
    <heading>EXAMPLE 89</heading> <heading>Preparation of Peptide Having SEQ ID NO. 91</heading> <p num="p-0269">
      <tables id="TABLE-US-00056" num="00056"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Ser Thr</td>
                <td class="description-td">[SEQ. ID. NO. 91]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0270">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3294.7.</p>
    <heading>EXAMPLE 90</heading> <heading>Preparation of Peptide Having SEQ ID NO. 92</heading> <p num="p-0271">
      <tables id="TABLE-US-00057" num="00057"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 92]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Leu Ser Lys Gln Met Ala Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0272">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3250.7.</p>
    <heading>EXAMPLE 91</heading> <heading>Preparation of Peptide Having SEQ ID NO. 93</heading> <p num="p-0273">
      <tables id="TABLE-US-00058" num="00058"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 93]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp pentylgly Ser Lys Gln Leu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Glu Ala Val Arg Leu Phe Ile</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0274">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3253.5.</p>
    <heading>EXAMPLE 92</heading> <heading>Preparation of Peptide Having SEQ ID NO. 94</heading> <p num="p-0275">
      <tables id="TABLE-US-00059" num="00059"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 94]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Naphthylala</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0276">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3289.5.</p>
    <heading>EXAMPLE 93</heading> <heading>Preparation of Peptide Having SEQ ID NO. 95</heading> <p num="p-0277">
      <tables id="TABLE-US-00060" num="00060"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 95]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">tButylgly Glu Trp Leu Lys</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0278">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3183.4.</p>
    <heading>EXAMPLE 94</heading> <heading>Preparation of Peptide Having SEQ ID NO. 96</heading> <p num="p-0279">
      <tables id="TABLE-US-00061" num="00061"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 96]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="203pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Asp</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0280">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3237.6.</p>
    <heading>EXAMPLE 95</heading> <heading>Preparation of Peptide Having SEQ ID NO. 97</heading> <p num="p-0281">
      <tables id="TABLE-US-00062" num="00062"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 97]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="203pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Phe Leu Lys Asn Gly Gly Pro Ser Ser-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0282">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3637.9.</p>
    <heading>EXAMPLE 96</heading> <heading>Preparation of Peptide Having SEQ ID NO. 98</heading> <p num="p-0283">
      <tables id="TABLE-US-00063" num="00063"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 98]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="203pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Trp Leu Lys Asn Gly-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0284">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3309.7.</p>
    <heading>EXAMPLE 97</heading> <heading>Preparation of Peptide Having SEQ ID NO. 99</heading> <p num="p-0285">
      <tables id="TABLE-US-00064" num="00064"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 99]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="203pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Trp Leu Lys Asn Gly Gly hPro Ser Ser Gly Ala</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">hPro hPro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0286">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Ecample 37. Double couplings are required at residues 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3711.1.</p>
    <heading>EXAMPLE 98</heading> <heading>Preparation of C-terminal Carboxylic Acid Peptides Corresponding to the Above C-terminal Amide Sequences for SEQ ID NOS. 7, 40-61, 68-75, 78-80 and 87-96</heading> <p num="p-0287">Peptides having the sequences of SEQ ID NOS. 7, 40-61, 68-75, 78-80 and 87-96 are assembled on the so called Wang resin (p-alkoxybenzylalacohol resin (Bachem, 0.54 mmole/g)) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry provides an experimentally determined (M).</p>
    <heading>EXAMPLE 99</heading> <heading>Preparation of C-terminal Carboxylic Acid Peptides Corresponding to the Above C-terminal Amide Sequences for SEQ ID NOS. 62-67, 76, 77 and 81-86</heading> <p num="p-0288">Peptides having the sequences of SEQ ID NOS. 62-67, 76, 77 and 81-86 are assembled on the 2-chlorotritylchloride resin (200-400 mesh), 2% DVB (Novabiochem, 0.4-1.0 mmole/g)) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry provides an experimentally determined (M).</p>
    <heading>EXAMPLE 100</heading> <heading>Preparation of Peptide Having SEQ ID NO. 100</heading> <p num="p-0289">
      <tables id="TABLE-US-00065" num="00065"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 100]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="203pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0290">The above amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.). In general, single-coupling cycles were used throughout the synthesis and Fast Moc (HBTU activation) chemistry was employed. Deprotection (Fmoc group removal)of the growing peptide chain was achieved using piperidine. Final deprotection of the completed peptide resin was achieved using a mixture of triethylsilane (0.2 mL), ethanedithiol (0.2 mL), anisole (0.2 mL), water (0.2 mL) and trifluoroacetic acid (15 mL) according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc.) The peptide was precipitated in ether/water (50 mL) and centrifuged. The precipitate was reconstituted in glacial acetic acid and lyophilized. The lyophilized peptide was dissolved in water). Crude purity was about 75%.</p>
    <p num="p-0291">Used in purification steps and analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).</p>
    <p num="p-0292">The solution containing peptide was applied to a preparative C-18 column and purified (10% to 40% Solvent B in Solvent A over 40 minutes). Purity of fractions was determined isocratically using a C-18 analytical column. Pure fractions were pooled furnishing the above-identified peptide. Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 19.2 minutes. Electrospray Mass Spectrometry (M): calculated 3171.6; found 3172.</p>
    <heading>EXAMPLE 101</heading> <heading>Preparation of Peptide Having SEQ ID NO. 101</heading> <p num="p-0293">
      <tables id="TABLE-US-00066" num="00066"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 101]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="203pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0294">The above amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.9 minutes. Electrospray Mass Spectrometry (M): calculated 3179.6; found 3180.</p>
    <heading>EXAMPLE 102</heading> <heading>Preparation of Peptide Having SEQ ID NO. 102</heading> <p num="p-0295">
      <tables id="TABLE-US-00067" num="00067"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 102]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="203pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0296">The above amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 37% to 47% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 12.2 minutes. Electrospray Mass Spectrometry (M): calculated 3251.6; found 3253.3.</p>
    <heading>EXAMPLE 103</heading> <heading>Preparation of Peptide Having SEQ ID NO. 103</heading> <p num="p-0297">
      <tables id="TABLE-US-00068" num="00068"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 103]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="203pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0298">The above amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 35% to 45% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 16.3 minutes. Electrospray Mass Spectrometry (M): calculated 3193.6; found 3197.</p>
    <heading>EXAMPLE 104</heading> <heading>Preparation of Peptide Having SEQ ID NO. 104</heading> <p num="p-0299">
      <tables id="TABLE-US-00069" num="00069"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 104]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="203pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0300">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3228.6.</p>
    <heading>EXAMPLE 105</heading> <heading>Preparation of Peptide Having SEQ ID NO. 105</heading> <p num="p-0301">
      <tables id="TABLE-US-00070" num="00070"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 105]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="203pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0302">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3234.7.</p>
    <heading>EXAMPLE 106</heading> <heading>Preparation of Peptide Having SEQ ID NO. 106</heading> <p num="p-0303">
      <tables id="TABLE-US-00071" num="00071"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 106]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0304">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3308.7.</p>
    <heading>EXAMPLE 107</heading> <heading>Preparation of Peptide Having SEQ ID NO. 107</heading> <p num="p-0305">
      <tables id="TABLE-US-00072" num="00072"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 107]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0306">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3250.7</p>
    <heading>EXAMPLE 108</heading> <heading>Preparation of Peptide Having SEQ ID NO. 108</heading> <p num="p-0307">
      <tables id="TABLE-US-00073" num="00073"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 108]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0308">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3252.6.</p>
    <heading>EXAMPLE 109</heading> <heading>Preparation of Peptide Having SEQ ID NO. 109</heading> <p num="p-0309">
      <tables id="TABLE-US-00074" num="00074"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 109]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Ala Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0310">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3200.6.</p>
    <heading>EXAMPLE 110</heading> <heading>Preparation of Peptide Having SEQ ID NO. 110</heading> <p num="p-0311">
      <tables id="TABLE-US-00075" num="00075"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 110]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Ala Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0312">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3143.5.</p>
    <heading>EXAMPLE 111</heading> <heading>Preparation of Peptide Having SEQ ID NO. 111</heading> <p num="p-0313">
      <tables id="TABLE-US-00076" num="00076"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 111]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0314">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3214.6.</p>
    <heading>EXAMPLE 112</heading> <heading>Preparation of Peptide Having SEQ ID NO. 112</heading> <p num="p-0315">
      <tables id="TABLE-US-00077" num="00077"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 112]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0316">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3157.5.</p>
    <heading>EXAMPLE 113</heading> <heading>Preparation of Peptide Having SEQ ID NO. 113</heading> <p num="p-0317">
      <tables id="TABLE-US-00078" num="00078"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 113]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Ala Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0318">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3184.6.</p>
    <heading>EXAMPLE 114</heading> <heading>Preparation of Peptide Having SEQ ID NO. 114</heading> <p num="p-0319">
      <tables id="TABLE-US-00079" num="00079"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 114]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Ala Phe Thr Ser Asp Leu Ser Lys</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0320">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3127.5.</p>
    <heading>EXAMPLE 115</heading> <heading>Preparation of Peptide Having SEQ ID NO. 115</heading> <p num="p-0321">
      <tables id="TABLE-US-00080" num="00080"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="right"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">[SEQ. ID. NO. 115]</td>
                <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="217pt" align="left"> </colspec> <colspec colname="2" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr NaphthylAla Thr Ser Asp Leu</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ile Glu Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0322">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3266.4.</p>
    <heading>EXAMPLE 116</heading> <heading>Preparation of Peptide Having SEQ ID NO. 116</heading> <p num="p-0323">
      <tables id="TABLE-US-00081" num="00081"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Naphthylala</td>
                <td class="description-td">[SEQ. ID. NO. 116]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Thr Ser Asp Leu Ser Lys Gln Leu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Glu Glu Ala Val Arg Leu Phe</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0324">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3209.4.</p>
    <heading>EXAMPLE 117</heading> <heading>Preparation of Peptide Having SEQ ID NO. 117</heading> <p num="p-0325">
      <tables id="TABLE-US-00082" num="00082"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Ser Ser</td>
                <td class="description-td">[SEQ. ID. NO. 117]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0326">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3200.6.</p>
    <heading>EXAMPLE 118</heading> <heading>Preparation of Peptide Having SEQ ID NO. 118</heading> <p num="p-0327">
      <tables id="TABLE-US-00083" num="00083"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Ser Ser</td>
                <td class="description-td">[SEQ. ID. NO. 118]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0328">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3143.5.</p>
    <heading>EXAMPLE 119</heading> <heading>Preparation of Peptide Having SEQ ID NO. 119</heading> <p num="p-0329">
      <tables id="TABLE-US-00084" num="00084"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ala</td>
                <td class="description-td">[SEQ. ID. NO. 119]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0330">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3198.6.</p>
    <heading>EXAMPLE 120</heading> <heading>Preparation of Peptide Having SEQ ID NO. 120</heading> <p num="p-0331">
      <tables id="TABLE-US-00085" num="00085"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ala</td>
                <td class="description-td">[SEQ. ID. NO. 120]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0332">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3141.5.</p>
    <heading>EXAMPLE 121</heading> <heading>Preparation of Peptide Having SEQ ID NO. 121</heading> <p num="p-0333">
      <tables id="TABLE-US-00086" num="00086"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 121]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ala Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0334">The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3170.6.</p>
    <heading>EXAMPLE 122</heading> <heading>Preparation of Peptide Having SEQ ID NO. 122</heading> <p num="p-0335">
      <tables id="TABLE-US-00087" num="00087"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 122]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ala Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0336">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3113.5.</p>
    <heading>EXAMPLE 123</heading> <heading>Preparation of Peptide Having SEQ ID NO. 123</heading> <p num="p-0337">
      <tables id="TABLE-US-00088" num="00088"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 123]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0338">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3228.6.</p>
    <heading>EXAMPLE 124</heading> <heading>Preparation of Peptide Having SEQ ID NO. 124</heading> <p num="p-0339">
      <tables id="TABLE-US-00089" num="00089"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 124]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0340">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3171.6.</p>
    <heading>EXAMPLE 125</heading> <heading>Preparation of Peptide Having SEQ ID NO. 125</heading> <p num="p-0341">
      <tables id="TABLE-US-00090" num="00090"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 125]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Ala Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0342">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3172.5.</p>
    <heading>EXAMPLE 126</heading> <heading>Preparation of Peptide Having SEQ ID NO. 126</heading> <p num="p-0343">
      <tables id="TABLE-US-00091" num="00091"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 126]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Ala Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0344">The above-identified amidated peptiden is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3115.4.</p>
    <heading>EXAMPLE 127</heading> <heading>Preparation of Peptide Having SEQ ID NO. 127</heading> <p num="p-0345">
      <tables id="TABLE-US-00092" num="00092"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 127]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Pentylgly Ser Lys Gln Met</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Glu Glu Ala Val Arg Leu Phe</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ile Glu Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0346">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3230.4.</p>
    <heading>EXAMPLE 128</heading> <heading>Preparation of Peptide Having SEQ ID NO. 128</heading> <p num="p-0347">
      <tables id="TABLE-US-00093" num="00093"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 128]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Pentylgly Ser Lys Gln Leu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Glu Glu Ala Val Arg Leu Phe</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0348">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3198.6.</p>
    <heading>EXAMPLE 129</heading> <heading>Preparation of Peptide Having SEQ ID NO. 129</heading> <p num="p-0349">
      <tables id="TABLE-US-00094" num="00094"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 129]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ala Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0350">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3141.5.</p>
    <heading>EXAMPLE 130</heading> <heading>Preparation of Peptide Having SEQ ID NO. 130</heading> <p num="p-0351">
      <tables id="TABLE-US-00095" num="00095"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 130]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ala Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0352">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3157.5.</p>
    <heading>EXAMPLE 131</heading> <heading>Preparation of Peptide Having SEQ ID NO. 131</heading> <p num="p-0353">
      <tables id="TABLE-US-00096" num="00096"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 131]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Ala Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0354">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3100.4.</p>
    <heading>EXAMPLE 132</heading> <heading>Preparation of Peptide Having SEQ ID NO. 132</heading> <p num="p-0355">
      <tables id="TABLE-US-00097" num="00097"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 132]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Ala Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0356">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3157.6.</p>
    <heading>EXAMPLE 133</heading> <heading>Preparation of Peptide Having SEQ ID NO. 133</heading> <p num="p-0357">
      <tables id="TABLE-US-00098" num="00098"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 133]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Ala Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0358">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3100.5.</p>
    <heading>EXAMPLE 134</heading> <heading>Preparation of Peptide Having SEQ ID NO. 134</heading> <p num="p-0359">
      <tables id="TABLE-US-00099" num="00099"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 134]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Ala Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0360">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3100.5.</p>
    <heading>EXAMPLE 135</heading> <heading>Preparation of Peptide Having SEQ ID NO. 135</heading> <p num="p-0361">
      <tables id="TABLE-US-00100" num="00100"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 135]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Ala Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0362">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3154.5.</p>
    <heading>EXAMPLE 136</heading> <heading>Preparation of Peptide Having SEQ ID NO. 136</heading> <p num="p-0363">
      <tables id="TABLE-US-00101" num="00101"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 136]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Ala Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0364">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3115.5.</p>
    <heading>EXAMPLE 137</heading> <heading>Preparation of Peptide Having SEQ ID NO. 137</heading> <p num="p-0365">
      <tables id="TABLE-US-00102" num="00102"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 137]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Pentylgly</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Glu Glu Ala Val Arg Leu Phe</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ile Glu Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0366">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3212.4.</p>
    <heading>EXAMPLE 138</heading> <heading>Preparation of Peptide Having SEQ ID NO. 138</heading> <p num="p-0367">
      <tables id="TABLE-US-00103" num="00103"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 138]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Pentylgly</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Glu Glu Ala Val Arg Leu Phe</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0368">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3173.4.</p>
    <heading>EXAMPLE 139</heading> <heading>Preparation of Peptide Having SEQ ID NO. 139</heading> <p num="p-0369">
      <tables id="TABLE-US-00104" num="00104"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 139]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Ala Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0370">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3156.6.</p>
    <heading>EXAMPLE 140</heading> <heading>Preparation of Peptide Having SEQ ID NO. 140</heading> <p num="p-0371">
      <tables id="TABLE-US-00105" num="00105"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 140]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Ala Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0372">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3099.5.</p>
    <heading>EXAMPLE 141</heading> <heading>Preparation of Peptide Having SEQ ID NO. 141</heading> <p num="p-0373">
      <tables id="TABLE-US-00106" num="00106"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 141]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Ala</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0374">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3156.6.</p>
    <heading>EXAMPLE 142</heading> <heading>Preparation of Peptide Having SEQ ID NO. 142</heading> <p num="p-0375">
      <tables id="TABLE-US-00107" num="00107"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 142]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Ala</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0376">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3099.5.</p>
    <heading>EXAMPLE 143</heading> <heading>Preparation of Peptide Having SEQ ID NO. 143</heading> <p num="p-0377">
      <tables id="TABLE-US-00108" num="00108"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 143]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ala Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0378">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3156.6.</p>
    <heading>EXAMPLE 144</heading> <heading>Preparation of Peptide Having SEQ ID NO. 144</heading> <p num="p-0379">
      <tables id="TABLE-US-00109" num="00109"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 144]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ala Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0380">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3099.5.</p>
    <heading>EXAMPLE 145</heading> <heading>Preparation of Peptide Having SEQ ID NO. 145</heading> <p num="p-0381">
      <tables id="TABLE-US-00110" num="00110"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 145]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Ala Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0382">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3186.6.</p>
    <heading>EXAMPLE 146</heading> <heading>Preparation of Peptide Having SEQ ID NO. 146</heading> <p num="p-0383">
      <tables id="TABLE-US-00111" num="00111"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 146]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Ala Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0384">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3129.5.</p>
    <heading>EXAMPLE 147</heading> <heading>Preparation of Peptide Having SEQ ID NO. 147</heading> <p num="p-0385">
      <tables id="TABLE-US-00112" num="00112"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 147]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Ala Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0386">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3129.5.</p>
    <heading>EXAMPLE 148</heading> <heading>Preparation of Peptide Having SEQ ID NO. 148</heading> <p num="p-0387">
      <tables id="TABLE-US-00113" num="00113"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 148]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Ala Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0388">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3072.4.</p>
    <heading>EXAMPLE 149</heading> <heading>Preparation of Peptide Having SEQ ID NO. 149</heading> <p num="p-0389">
      <tables id="TABLE-US-00114" num="00114"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 149]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Ala Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0390">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3172.5.</p>
    <heading>EXAMPLE 150</heading> <heading>Preparation of Peptide Having SEQ ID NO. 150</heading> <p num="p-0391">
      <tables id="TABLE-US-00115" num="00115"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 150]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Ala Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0392">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3115.5.</p>
    <heading>EXAMPLE 151</heading> <heading>Preparation of Peptide Having SEQ ID NO. 151</heading> <p num="p-0393">
      <tables id="TABLE-US-00116" num="00116"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 151]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Naphthylala</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ile Glu Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0394">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3266.4.</p>
    <heading>EXAMPLE 152</heading> <heading>Preparation of Peptide Having SEQ ID NO. 152</heading> <p num="p-0395">
      <tables id="TABLE-US-00117" num="00117"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 152]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Naphthylala</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ile Glu Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0396">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3209.4.</p>
    <heading>EXAMPLE 153</heading> <heading>Preparation of Peptide Having SEQ ID NO. 153</heading> <p num="p-0397">
      <tables id="TABLE-US-00118" num="00118"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 153]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Val Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0398">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3200.6.</p>
    <heading>EXAMPLE 154</heading> <heading>Preparation of Peptide Having SEQ ID NO. 154</heading> <p num="p-0399">
      <tables id="TABLE-US-00119" num="00119"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 154]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Val Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0400">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3143.5.</p>
    <heading>EXAMPLE 155</heading> <heading>Preparation of Peptide Having SEQ ID NO. 155</heading> <p num="p-0401">
      <tables id="TABLE-US-00120" num="00120"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 155]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">tButylgly Glu Trp Leu Lys</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0402">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3216.5.</p>
    <heading>EXAMPLE 156</heading> <heading>Preparation of Peptide Having SEQ ID NO. 156</heading> <p num="p-0403">
      <tables id="TABLE-US-00121" num="00121"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 156]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">tButylgly Glu Phe Leu Lys</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0404">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3159.4.</p>
    <heading>EXAMPLE 157</heading> <heading>Preparation of Peptide Having SEQ ID NO. 157</heading> <p num="p-0405">
      <tables id="TABLE-US-00122" num="00122"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 157]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Asp</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0406">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3200.6.</p>
    <heading>EXAMPLE 158</heading> <heading>Preparation of Peptide Having SEQ ID NO. 158</heading> <p num="p-0407">
      <tables id="TABLE-US-00123" num="00123"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 158]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Asp</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0408">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3143.5.</p>
    <heading>EXAMPLE 159</heading> <heading>Preparation of Peptide Having SEQ ID NO. 159</heading> <p num="p-0409">
      <tables id="TABLE-US-00124" num="00124"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 159]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ala Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0410">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3099.5.</p>
    <heading>EXAMPLE 160</heading> <heading>Preparation of Peptide Having SEQ ID NO. 160</heading> <p num="p-0411">
      <tables id="TABLE-US-00125" num="00125"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 160]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ala Leu Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0412">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3081.4.</p>
    <heading>EXAMPLE 161</heading> <heading>Preparation of Peptide Having SEQ ID NO. 161</heading> <p num="p-0413">
      <tables id="TABLE-US-00126" num="00126"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 161]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Ala Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0414">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3172.5.</p>
    <heading>EXAMPLE 162</heading> <heading>Preparation of Peptide Having SEQ ID NO. 162</heading> <p num="p-0415">
      <tables id="TABLE-US-00127" num="00127"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 162]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Ala Lys Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0416">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3115.5.</p>
    <heading>EXAMPLE 163</heading> <heading>Preparation of Peptide Having SEQ ID NO. 163</heading> <p num="p-0417">
      <tables id="TABLE-US-00128" num="00128"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 163]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Ala Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0418">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3157.5.</p>
    <heading>EXAMPLE 164</heading> <heading>Preparation of Peptide Having SEQ ID NO. 164</heading> <p num="p-0419">
      <tables id="TABLE-US-00129" num="00129"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 164]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Ala Asn-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0420">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3100.4.</p>
    <heading>EXAMPLE 165</heading> <heading>Preparation of Peptide Having SEQ ID NO. 165</heading> <p num="p-0421">
      <tables id="TABLE-US-00130" num="00130"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 165]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Ala-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0422">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3171.6.</p>
    <heading>EXAMPLE 166</heading> <heading>Preparation of Peptide Having SEQ ID NO. 166</heading> <p num="p-0423">
      <tables id="TABLE-US-00131" num="00131"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Asp Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 166]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Ala-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0424">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3114.5.</p>
    <heading>EXAMPLE 167</heading> <heading>Preparation of Peptide Having SEQ ID NO. 167</heading> <p num="p-0425">
      <tables id="TABLE-US-00132" num="00132"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 167]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala Pro Pro Pro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0426">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4033.5.</p>
    <heading>EXAMPLE 168</heading> <heading>Preparation of Peptide Having SEQ ID NO. 168</heading> <p num="p-0427">
      <tables id="TABLE-US-00133" num="00133"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Ala Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 168]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala Pro Pro Pro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0428">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3984.4.</p>
    <heading>EXAMPLE 169</heading> <heading>Preparation of Peptide Having SEQ ID NO. 169</heading> <p num="p-0429">
      <tables id="TABLE-US-00134" num="00134"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Ala Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 169]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala Pro Pro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0430">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4016.5.</p>
    <heading>EXAMPLE 170</heading> <heading>Preparation of Peptide Having SEQ ID NO. 170</heading> <p num="p-0431">
      <tables id="TABLE-US-00135" num="00135"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 170]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ala Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala Pro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0432">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3861.3.</p>
    <heading>EXAMPLE 171</heading> <heading>Preparation of Peptide Having SEQ ID NO. 171</heading> <p num="p-0433">
      <tables id="TABLE-US-00136" num="00136"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 171]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Ala Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala Pro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0434">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3746.1.</p>
    <heading>EXAMPLE 172</heading> <heading>Preparation of Peptide Having SEQ ID NO. 172</heading> <p num="p-0435">
      <tables id="TABLE-US-00137" num="00137"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 172]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0436">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3742.1.</p>
    <heading>EXAMPLE 173</heading> <heading>Preparation of Peptide Having SEQ ID NO. 173</heading> <p num="p-0437">
      <tables id="TABLE-US-00138" num="00138"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Ala Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 173]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0438">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3693.1.</p>
    <heading>EXAMPLE 174</heading> <heading>Preparation of Peptide Having SEQ ID NO. 174</heading> <p num="p-0439">
      <tables id="TABLE-US-00139" num="00139"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Ala Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 174]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0440">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3751.2.</p>
    <heading>EXAMPLE 175</heading> <heading>Preparation of Peptide Having SEQ ID NO. 175</heading> <p num="p-0441">
      <tables id="TABLE-US-00140" num="00140"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 175]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ala Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0442">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3634.1.</p>
    <heading>EXAMPLE 176</heading> <heading>Preparation of Peptide Having SEQ ID NO. 176</heading> <p num="p-0443">
      <tables id="TABLE-US-00141" num="00141"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 176]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0444">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3526.9.</p>
    <heading>EXAMPLE 177</heading> <heading>Preparation of Peptide Having SEQ ID NO. 177</heading> <p num="p-0445">
      <tables id="TABLE-US-00142" num="00142"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Ala Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 177]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn Gly Gly Pro</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0446">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3477.9.</p>
    <heading>EXAMPLE 178</heading> <heading>Preparation of Peptide Having SEQ ID NO. 178</heading> <p num="p-0447">
      <tables id="TABLE-US-00143" num="00143"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Ala Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 178]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0448">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3519.9.</p>
    <heading>EXAMPLE 179</heading> <heading>Preparation of Peptide Having SEQ ID NO. 179</heading> <p num="p-0449">
      <tables id="TABLE-US-00144" num="00144"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 179]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ala Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn Gly Gly-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0450">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3307.7.</p>
    <heading>EXAMPLE 180</heading> <heading>Preparation of Peptide Having SEQ ID NO. 180</heading> <p num="p-0451">
      <tables id="TABLE-US-00145" num="00145"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 180]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn Gly-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0452">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3186.5.</p>
    <heading>EXAMPLE 181</heading> <heading>Preparation of Peptide Having SEQ ID NO. 181</heading> <p num="p-0453">
      <tables id="TABLE-US-00146" num="00146"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Ala Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 181]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly tPro</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Ser Gly Ala tPro tPro</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">tPro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0454">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Double couplings are required at residues 37,36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4121.1.</p>
    <heading>EXAMPLE 182</heading> <heading>Preparation of Peptide Having SEQ ID NO. 182</heading> <p num="p-0455">
      <tables id="TABLE-US-00147" num="00147"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Ala Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 182]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala tPro tPro tPro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0456">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Double couplings are required at residues 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4173.2.</p>
    <heading>EXAMPLE 183</heading> <heading> </heading> <p num="p-0457">Preparation of Peptide Having SEQ ID NO. 183</p>
    <p num="p-0458">
      <tables id="TABLE-US-00148" num="00148"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 183]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ala Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly NMeala</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Ser Gly Ala NMeala</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">NMeala-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0459">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Compound 1. Double couplings are required at residues 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3796.1.</p>
    <heading>EXAMPLE 184</heading> <heading>Preparation of Peptide Having SEQ ID NO. 184</heading> <p num="p-0460">
      <tables id="TABLE-US-00149" num="00149"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 184]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly hPro</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Ser Gly Ala hPro-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0461">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. A double coupling is required at residue 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3871.1.</p>
    <heading>EXAMPLE 185</heading> <heading>Preparation of Peptide Having SEQ ID NO. 185</heading> <p num="p-0462">
      <tables id="TABLE-US-00150" num="00150"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="133pt" align="left"> </colspec> <colspec colname="2" colwidth="84pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Ala Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 185]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0463">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3750.2.</p>
    <heading>EXAMPLE 186</heading> <heading>Preparation of Peptide Having SEQ ID NO. 186</heading> <p num="p-0464">
      <tables id="TABLE-US-00151" num="00151"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">His Gly Asp Ala Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 186]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0465">The above-identified amdiated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3408.8.</p>
    <heading>EXAMPLE 187</heading> <heading>Preparation of Peptide Having SEQ ID NO. 187</heading> <p num="p-0466">
      <tables id="TABLE-US-00152" num="00152"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Glu Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 187]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Met Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Trp Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala Pro Pro Pro Ser-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0467">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4120.6.</p>
    <heading>EXAMPLE 188</heading> <heading>Preparation of Peptide Having SEQ ID NO. 188</heading> <p num="p-0468">
      <tables id="TABLE-US-00153" num="00153"> <table frame="none" colsep="0" rowsep="0" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="140pt" align="left"> </colspec> <colspec colname="2" colwidth="77pt" align="left"> </colspec> <colspec colname="3" colwidth="0pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ala Gly Ala Gly Thr Phe Thr Ser</td>
                <td class="description-td">[SEQ. ID. NO. 188]</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Asp Leu Ser Lys Gln Leu Glu Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Glu Ala Val Arg Leu Phe Ile Glu</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Phe Leu Lys Asn Gly Gly Pro Ser</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Ser Gly Ala Pro Pro Pro Ser-NH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0469">The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4005.5.</p>
    <heading>EXAMPLE 189</heading> <heading>Preparation of C-terminal Carboxylic Acid Peptides Corresponding to the Above C-terminal Amide Sequences for Peptides Having SEQ ID NOS. 100-166. 172-177. 179-180 and 185-188</heading> <p num="p-0470">C-terminal carboxylic acid peptides corresponding to amidated having SEQ ID NOS. 100-166, 172-177, 179-180 and 185-188 are assembled on the so called Wang resin (p-alkoxybenzylalacohol resin (Bachem, 0.54 mmole/g)) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to that described in Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry provides an experimentally determined (M).</p>
    <heading>EXAMPLE 190</heading> <heading>Preparation of C-terminal Carboxylic Acid Peptides Corresponding to the Above C-terminal Amide Sequences for Peptides Having SEQ ID NOS. 167-171, 178 and 181-184</heading> <p num="p-0471">C-terminal carboxylic acid eptides corresponding to amidated SEQ ID NOS. 167-171, 178 and 181-184 are assembled on the 2-chlorotritylchloride resin (200-400 mesh), 2% DVB (Novabiochem, 0.4-1.0 mmole/g)) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to that described in Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry provides an experimentally determined (M).</p>
    <p num="p-0472">Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the following claims.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5118666">US5118666</a></td><td class="patent-data-table-td patent-date-value">Jun 1, 1990</td><td class="patent-data-table-td patent-date-value">Jun 2, 1992</td><td class="patent-data-table-td ">The General Hospital Corporation</td><td class="patent-data-table-td ">Insulinotropic hormone</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5120712">US5120712</a></td><td class="patent-data-table-td patent-date-value">Jun 1, 1990</td><td class="patent-data-table-td patent-date-value">Jun 9, 1992</td><td class="patent-data-table-td ">The General Hospital Corporation</td><td class="patent-data-table-td ">Insulinotropic hormone</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5187154">US5187154</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 13, 1990</td><td class="patent-data-table-td patent-date-value">Feb 16, 1993</td><td class="patent-data-table-td ">Board Of Regents, The University Of Texas System</td><td class="patent-data-table-td ">Administering cholecystokinins</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5264372">US5264372</a></td><td class="patent-data-table-td patent-date-value">Mar 15, 1991</td><td class="patent-data-table-td patent-date-value">Nov 23, 1993</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Receptor-based screening methods for amylin agonists and antagonists</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5424286">US5424286</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 24, 1993</td><td class="patent-data-table-td patent-date-value">Jun 13, 1995</td><td class="patent-data-table-td ">Eng; John</td><td class="patent-data-table-td ">Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5512549">US5512549</a></td><td class="patent-data-table-td patent-date-value">Oct 18, 1994</td><td class="patent-data-table-td patent-date-value">Apr 30, 1996</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Antidiabetic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5545618">US5545618</a></td><td class="patent-data-table-td patent-date-value">Dec 10, 1993</td><td class="patent-data-table-td patent-date-value">Aug 13, 1996</td><td class="patent-data-table-td ">Buckley; Douglas I.</td><td class="patent-data-table-td ">GLP-1 analogs useful for diabetes treatment</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5574008">US5574008</a></td><td class="patent-data-table-td patent-date-value">Aug 30, 1994</td><td class="patent-data-table-td patent-date-value">Nov 12, 1996</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Antidiabetic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5686511">US5686511</a></td><td class="patent-data-table-td patent-date-value">Jun 28, 1996</td><td class="patent-data-table-td patent-date-value">Nov 11, 1997</td><td class="patent-data-table-td ">The Valspar Corporation</td><td class="patent-data-table-td ">Esterifying epoxy resin with carboxyl polymer and quenching</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6191102">US6191102</a></td><td class="patent-data-table-td patent-date-value">Oct 30, 1997</td><td class="patent-data-table-td patent-date-value">Feb 20, 2001</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Glucagon like peptide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6858576">US6858576</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 8, 1997</td><td class="patent-data-table-td patent-date-value">Feb 22, 2005</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods for regulating gastrointestinal motility</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6902744">US6902744</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 14, 2000</td><td class="patent-data-table-td patent-date-value">Jun 7, 2005</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Exendin agonist formulations and methods of administration thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6924264">US6924264</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 28, 2000</td><td class="patent-data-table-td patent-date-value">Aug 2, 2005</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">chain extension of polypeptides using polymers selected from polyethylene glycol, polylactams, albumin, gelatin, acrylic polymers, fatty acids, polysaccharides, lipid and/or dextrans; antidiabetic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="http://www.google.com/url?id=XXt_BAABERAJ&amp;q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DAU%26NR%3D3173297A%26KC%3DA%26FT%3DD&amp;usg=AFQjCNHpSYf4YLAC-GFdqm1-LHjHM4q4oQ">AU3173297A</a></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1990011296A1?cl=en">WO1990011296A1</a></td><td class="patent-data-table-td patent-date-value">Mar 20, 1989</td><td class="patent-data-table-td patent-date-value">Oct 4, 1990</td><td class="patent-data-table-td ">Gen Hospital Corp</td><td class="patent-data-table-td ">Insulinotropic hormone</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1991011457A1?cl=en">WO1991011457A1</a></td><td class="patent-data-table-td patent-date-value">Jan 24, 1991</td><td class="patent-data-table-td patent-date-value">Aug 8, 1991</td><td class="patent-data-table-td ">Douglas I Buckley</td><td class="patent-data-table-td ">Glp-1 analogs useful for diabetes treatment</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1993018786A1?cl=en">WO1993018786A1</a></td><td class="patent-data-table-td patent-date-value">Mar 18, 1993</td><td class="patent-data-table-td patent-date-value">Sep 30, 1993</td><td class="patent-data-table-td ">Suad Efendic</td><td class="patent-data-table-td ">Use of a peptide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1993025579A1?cl=en">WO1993025579A1</a></td><td class="patent-data-table-td patent-date-value">Apr 14, 1993</td><td class="patent-data-table-td patent-date-value">Dec 23, 1993</td><td class="patent-data-table-td ">Glenn C Andrews</td><td class="patent-data-table-td ">Glucagon-like peptide and insulinotropin derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1995007098A1?cl=en">WO1995007098A1</a></td><td class="patent-data-table-td patent-date-value">Sep 7, 1994</td><td class="patent-data-table-td patent-date-value">Mar 16, 1995</td><td class="patent-data-table-td ">Amylin Pharmaceuticals Inc</td><td class="patent-data-table-td ">Methods for regulating gastrointestinal motility</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1996006626A1?cl=en">WO1996006626A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 26, 1994</td><td class="patent-data-table-td patent-date-value">Mar 7, 1996</td><td class="patent-data-table-td ">Avram Goldstein</td><td class="patent-data-table-td ">Analgesic method with dynorphin analogues truncated at the n-terminus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1998005351A1?cl=en">WO1998005351A1</a></td><td class="patent-data-table-td patent-date-value">Aug 8, 1997</td><td class="patent-data-table-td patent-date-value">Feb 12, 1998</td><td class="patent-data-table-td ">Amylin Pharmaceuticals Inc</td><td class="patent-data-table-td ">Methods for regulating gastrointestinal motility</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1998019698A1?cl=en">WO1998019698A1</a></td><td class="patent-data-table-td patent-date-value">Nov 4, 1997</td><td class="patent-data-table-td patent-date-value">May 14, 1998</td><td class="patent-data-table-td ">Lilly Co Eli</td><td class="patent-data-table-td ">Use of glp-1 analogs and derivatives administered peripherally in regulation of obesity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1998030231A1?cl=en">WO1998030231A1</a></td><td class="patent-data-table-td patent-date-value">Jan 7, 1998</td><td class="patent-data-table-td patent-date-value">Jul 16, 1998</td><td class="patent-data-table-td ">Amylin Pharmaceuticals Inc</td><td class="patent-data-table-td ">Use of exendins and agonists thereof for the reduction of food intake</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1999007404A1?cl=en">WO1999007404A1</a></td><td class="patent-data-table-td patent-date-value">Aug 6, 1998</td><td class="patent-data-table-td patent-date-value">Feb 18, 1999</td><td class="patent-data-table-td ">Amylin Pharmaceuticals Inc</td><td class="patent-data-table-td ">Novel exendin agonist compounds</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Adelhorst, K., et al, "<a href='http://scholar.google.com/scholar?q="Structure-activity+studies+of+glucagon-like+peptide-1+%28GLP-1%29%2C"'>Structure-activity studies of glucagon-like peptide-1 (GLP-1),</a>" J. Bio Chem 269(9):6275-8 (1994).</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bartlett, et al, "<a href='http://scholar.google.com/scholar?q="Inhibition+of+Chymotrypsin+by+Phosphonate+and+Phosphonamidate+Peptide+Analogs%2C"'>Inhibition of Chymotrypsin by Phosphonate and Phosphonamidate Peptide Analogs,</a>" Bioorg. Chem. 14:356-377 (1986).</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bayer et al., "<a href='http://scholar.google.com/scholar?q="Advances+in+Poison+Management%2C"'>Advances in Poison Management,</a>" Clin. Chem., 42(8)(B):1361-66 (1996).</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bhavsar, "<a href='http://scholar.google.com/scholar?q="Inhibition+of+gastric+emptying+and+of+food+intake+appear+to+be+independently+controlled+in+rodents%2C"'>Inhibition of gastric emptying and of food intake appear to be independently controlled in rodents,</a>" Soc. Neurosci. Abst. 21:460 (188.8)(1995).</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Buffer solution (updated 2007) Wikipedia, "<a href='http://scholar.google.com/scholar?q="Commone+buffer+compounds+used+in+biology"'>Commone buffer compounds used in biology</a>", http://en.wikipedia.org./□□wiki/Buffer&lt;SUB&gt;-&lt;/SUB&gt;solution, p. 1.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Chantry et al. (1991) Cross-reactivity of amylin with calcitonin-gene-related peptide binding sites in rat liver and skeletal muscle membranes. Biochem. J. vol. 277 (Pt 1), pp. 139-143.</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Cohen, et al, The Pico Tag Method; A Manual of Advanced Techniques for Amino Acid Analysis, pp. 11-52, Millipore Corporation (1989).</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Cohen, S.A., Meys, M., and Tarrin, T.L. (1989), The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis, pp. 11-52, Millipore Corporation, Milford, MA).</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">D'Alessio et al. "<a href='http://scholar.google.com/scholar?q="Elimination+of+the+Action+of+glucagon-like+Peptide+1+Causes+an+Impairment+of+glucose+tolerance+after+Nutrient+Ingestion+by+Healthy+Baboons%2C"'>Elimination of the Action of glucagon-like Peptide 1 Causes an Impairment of glucose tolerance after Nutrient Ingestion by Healthy Baboons,</a>" J. Clin. Invest., 97:133-38, 1996.</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">D'Alessio et al., "<a href='http://scholar.google.com/scholar?q="Glucagon-like+Peptide+1+Enhances+Glucose+Tolerance+Both+by+Stimulation+of+Insulin+Release+and+by+Increasing+Insulin-independent+Glucose+Disposal%2C"'>Glucagon-like Peptide 1 Enhances Glucose Tolerance Both by Stimulation of Insulin Release and by Increasing Insulin-independent Glucose Disposal,</a>" J. Clin. Invest., 93:2263-66 (1994).</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Daniel et al. "<a href='http://scholar.google.com/scholar?q="Use+of+Glucagon+in+the+Treatment+of+Acute+Diverticulitis%2C"'>Use of Glucagon in the Treatment of Acute Diverticulitis,</a>" Br. Med. J., 3:720, 1974.</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Dhillo et al. (2003) Paraventricular nucleus administration of calcitonin gene-related peptide inhibits food intake and stimulates the hypothalamo-pituitary-adrenal axis. Endocrinology. vol. 144, No. 4, pp. 1420-1425.</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Eissele et al. "<a href='http://scholar.google.com/scholar?q="Rat+Gastric+somatostatin+and+Gastrin+Release%3A+Interactions+of+Exendin-4+and+Truncated+Glucagon-Like+Peptide-1+%28GLP-1%29+Amide%2C"'>Rat Gastric somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-Like Peptide-1 (GLP-1) Amide,</a>" Life Sci., 55:629-34, 1994.</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Eng et al. "<a href='http://scholar.google.com/scholar?q="Isolation+and+Characterization+of+Exendin-4%2C+an+Exendin-3+Analogue%2C+from+Heloderma+suspectum+Venom"'>Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from Heloderma suspectum Venom</a>", J. Biol. Chem., 267:7402-05, 1992.</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Eng et al. "<a href='http://scholar.google.com/scholar?q="Purification+and+Structure+of+Exendin-3%2C+a+New+Pancreatic+Secretagogue+Isolated+from+Heloderma+horridum+Venom%2C"'>Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated from Heloderma horridum Venom,</a>" J. Biol. Chem., 265:20259-62, 1990.</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Fehmann et al. "<a href='http://scholar.google.com/scholar?q="Stable+Expression+of+the+Rat+GLP-1+Receptor+in+CHO+Cells%3A+Activation+and+Binding+Characteristics+Utilizing+GLP-I%287-36%29-Amide%2C+Oxyntomodulin%2C+Exendin-4%2C+and+Exendin%289-39%29%2C"'>Stable Expression of the Rat GLP-1 Receptor in CHO Cells: Activation and Binding Characteristics Utilizing GLP-I(7-36)-Amide, Oxyntomodulin, Exendin-4, and Exendin(9-39),</a>" Peptides 15 (3): 453-6, 1994.</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Fehmann et al. "<a href='http://scholar.google.com/scholar?q="Stable+Expression+of+the+Rat+GLP-I+Receptor+in+CHO+Cells%3A+Activation+and+Binding+Characteristics+Utilizing+GLP-I%287-36%29-Amide%2C+Oxyntomodulin%2C+Exendin-4%2C+and+Exendin%289-39%29%2C"'>Stable Expression of the Rat GLP-I Receptor in CHO Cells: Activation and Binding Characteristics Utilizing GLP-I(7-36)-Amide, Oxyntomodulin, Exendin-4, and Exendin(9-39),</a>" Peptides 15 (3): 453-6, 1994.</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ferguson et al. "<a href='http://scholar.google.com/scholar?q="Cell-Surface+Anchoring+of+Proteins+Via+Glycosylphosphatidylinositol+Structures"'>Cell-Surface Anchoring of Proteins Via Glycosylphosphatidylinositol Structures</a>", Annu. Rev. Biochem. 57:285-320 (1988).</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ferguson et al. "<a href='http://scholar.google.com/scholar?q="Cell-Surface+Anchoring+of+Proteins+Via+Glycosylphosphatidylinositol+Structures"'>Cell-Surface Anchoring of Proteins Via Glycosylphosphatidylinositol Structures</a>", Annu. Rev. Biochem. 57:285-320, 1988.</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Gedulin et al. "<a href='http://scholar.google.com/scholar?q="Comparison+of+Effects+of+Amylin%2C+Glucagon-like+Peptide-1+and+Exendin-4+to+Inhibit+Pentagastrin-Stimulated+Gastric+Acid+Secretion%2C"'>Comparison of Effects of Amylin, Glucagon-like Peptide-1 and Exendin-4 to Inhibit Pentagastrin-Stimulated Gastric Acid Secretion,</a>" Diabetologia, 40 (Suppl. 1):A300 (Abstract 1181) (1997) 8:228, 1979.</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">GenBank Accession No. CAA24759, Feb. 9, 1999.</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Glauser et al. "<a href='http://scholar.google.com/scholar?q="Intravenous+glucagon+in+the+Management+of+Esophageal+Food+Obstruction"'>Intravenous glucagon in the Management of Esophageal Food Obstruction</a>", J. Am. Coll. Emergency Physns, 8:228, 1979.</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Goke et al. "<a href='http://scholar.google.com/scholar?q="Exendin-4+Is+a+High+Potency+Agonist+and+Truncated+Exendin-%289-39%29-amide+an+Antagonist+at+the+Glucagon-like+Peptide+1-%287-36%29-amide+Receptor+of+Insulin-secreting+beta-Cells"'>Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting beta-Cells</a>", J. Biol. Chem., 268:19650-55, 1993.</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Goke et al. "<a href='http://scholar.google.com/scholar?q="Exendin-4+Is+a+High+Potency+Agonist+and+Truncated+Exendin-%289-39%29-amide+an+Antagonist+at+the+Glucagon-like+Peptide+1-%287-36%29-amide+Receptor+of+Insulin-secreting+-Cells"'>Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting -Cells</a>", J. Biol. Chem., 268:19650-55, 1993.</td></tr><tr><td class="patent-data-table-td ">25</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Goldstone et al, FEBS Letters, vol. 415, pp. 134-138, 1997.</td></tr><tr><td class="patent-data-table-td ">26</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Holst, "<a href='http://scholar.google.com/scholar?q="Glucagonlike+Peptide-1%3A+A+Newly+Discovered+Gastrointestinal+Hormone%2C"'>Glucagonlike Peptide-1: A Newly Discovered Gastrointestinal Hormone,</a>" Gastroenterology, 107:1848-55 (1994).</td></tr><tr><td class="patent-data-table-td ">27</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Introduction to Cleavage Techniques, Applied Biosystems, Inc., 1990, pp. 6-12.</td></tr><tr><td class="patent-data-table-td ">28</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kodama, J., et al, "<a href='http://scholar.google.com/scholar?q="Effect+of+Captopril+on+Glucose+Concentration+Possible+Role+of+Augmented+Postprandial+Forearm+Blood+Flow%2C"'>Effect of Captopril on Glucose Concentration Possible Role of Augmented Postprandial Forearm Blood Flow,</a>" Diabetes Care 13(11):1109-1111 (1990).</td></tr><tr><td class="patent-data-table-td ">29</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kolligs et al. "<a href='http://scholar.google.com/scholar?q="Reduction+of+the+Incretin+effect+in+Rats+by+the+Glucagon-Like+Peptide+1+Receptor+antagonist+Exendin%289-39%29+Amide"'>Reduction of the Incretin effect in Rats by the Glucagon-Like Peptide 1 Receptor antagonist Exendin(9-39) Amide</a>", Diabetes, 44:16-19, 1995.</td></tr><tr><td class="patent-data-table-td ">30</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kolligs, et al, "<a href='http://scholar.google.com/scholar?q="Reduction+of+the+incretin+effect+in+rats+by+the+glucagon-like+peptide-1+receptor+antagonist+exendin+%289-39%29+amide%2C"'>Reduction of the incretin effect in rats by the glucagon-like peptide-1 receptor antagonist exendin (9-39) amide,</a>" Diabetes 44:16-19 (1995).</td></tr><tr><td class="patent-data-table-td ">31</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lawler et al., "<a href='http://scholar.google.com/scholar?q="Comparison+of+Effects+of+Amylin%2C+Glucagon-like+Peptide-1+%28GLP-1%29+and+Exendin-4+to+Inhibit+Pentagastrin-Stimulated+Gastric+Acid+Secretion+in+Rats%2C"'>Comparison of Effects of Amylin, Glucagon-like Peptide-1 (GLP-1) and Exendin-4 to Inhibit Pentagastrin-Stimulated Gastric Acid Secretion in Rats,</a>" Gastroenterology, 112(4):A194, (1997).</td></tr><tr><td class="patent-data-table-td ">32</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Leibel, R.L., et al, "<a href='http://scholar.google.com/scholar?q="Changes+in+Energy+Expenditure+Resulting+from+Altered+Body+Weight%2C"'>Changes in Energy Expenditure Resulting from Altered Body Weight,</a>" New England Journal of Medicine 332(10):621-628 (1995).</td></tr><tr><td class="patent-data-table-td ">33</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lithell, et al, "<a href='http://scholar.google.com/scholar?q="Insulin+Sensitivity+in+Newly+Detected+Hypertensive+Patients%3A+Influence+of+Captopril+and+Other+Antihypertensive+Agents+on+Insulin+Sensitivity+and+Related+Biological+Parameters%2C"'>Insulin Sensitivity in Newly Detected Hypertensive Patients: Influence of Captopril and Other Antihypertensive Agents on Insulin Sensitivity and Related Biological Parameters,</a>" J. Cardiovasc. Pharmacol. 15 (Supp 5):S46-S52 (1990).</td></tr><tr><td class="patent-data-table-td ">34</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Malhotra et al. "<a href='http://scholar.google.com/scholar?q="Exendin-4%2C+a+new+peptide+from+Heloderma+suspectum+venom%2C+potentiates+cholecystokinin-induced+amylase+release+from+rat+pancreatic+acini"'>Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini</a>", Regulatory Peptides, 41:149-56, 1992.</td></tr><tr><td class="patent-data-table-td ">35</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Miholic et al., "<a href='http://scholar.google.com/scholar?q="Glucagon-like+Peptide-1+%28GLP-1%29%2C+Entleerung+des+Magenersatzes+und+das+Dumpingsyndrom+nach+Gastrektomie%2C"'>Glucagon-like Peptide-1 (GLP-1), Entleerung des Magenersatzes und das Dumpingsyndrom nach Gastrektomie,</a>" Chirurgishes Forum, 1991, pp. 429-432 (English abstract and International Search Report in which the article is referenced are attached).</td></tr><tr><td class="patent-data-table-td ">36</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Montrose-Rafizadeh et al. "<a href='http://scholar.google.com/scholar?q="Structure-function+Analysis+of+Exendin-4+%2F+GLP-1+Analogs"'>Structure-function Analysis of Exendin-4 / GLP-1 Analogs</a>", Diabetes, 45(Suppl. 2):152A, 1996.</td></tr><tr><td class="patent-data-table-td ">37</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Nauck et al., "<a href='http://scholar.google.com/scholar?q="Effects+of+Subcutaneous+Glucagon-like+Peptide+1+%28GLP-1+%5B7-36+Amide%5D%29+in+Patients+with+Type+2-Diabetes%2C"'>Effects of Subcutaneous Glucagon-like Peptide 1 (GLP-1 [7-36 Amide]) in Patients with Type 2-Diabetes,</a>" Diabetologia, Abstract A148, 38 Supp. 1:A39 (1995).</td></tr><tr><td class="patent-data-table-td ">38</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Navarro, M. et al., "<a href='http://scholar.google.com/scholar?q="Colocalization+of+Glucagon-Like+Peptide-1+%28GLP-1%29+Receptors%2C+Glucose+Transporter+GLUT-2%2C+and+Glucokinase+mRNAs+in+Rat+Hypothalamic+Cells%3A+Evidence+for+a+Role+of+GLP-1+Receptor+Agonists+as+an+Inhibitory+Signal+for+Food+and+Water+Intake%2C"'>Colocalization of Glucagon-Like Peptide-1 (GLP-1) Receptors, Glucose Transporter GLUT-2, and Glucokinase mRNAs in Rat Hypothalamic Cells: Evidence for a Role of GLP-1 Receptor Agonists as an Inhibitory Signal for Food and Water Intake,</a>" Journal of Neurochemistry, 67:1982-1991 (1996).</td></tr><tr><td class="patent-data-table-td ">39</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">O'Halloran et al. "<a href='http://scholar.google.com/scholar?q="Glucagon-like+peptide-1+%287-36%29-NH%26lt%3BSUB%26gt%3B2%26lt%3B%2FSUB%26gt%3B%3A+a+physiological+inhibitor+of+gastric+acid+secretion+in+man%2C"'>Glucagon-like peptide-1 (7-36)-NH&lt;SUB&gt;2&lt;/SUB&gt;: a physiological inhibitor of gastric acid secretion in man,</a>" J Endocrinol 126 (1): 169-73, 1990.</td></tr><tr><td class="patent-data-table-td ">40</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">O'Halloran et al. "<a href='http://scholar.google.com/scholar?q="Glucagon-like+peptide-1+%287-36%29-NH%26lt%3BSUB%26gt%3B2%26lt%3B%2FSUB%26gt%3B%3A+a+physiological+inhibitor+of+gastric+acid+secretion+in+man%2C"'>Glucagon-like peptide-1 (7-36)-NH&lt;SUB&gt;2&lt;/SUB&gt;: a physiological inhibitor of gastric acid secretion in man,</a>" J. Endocrinol 126 (1): 169-73 (1990).</td></tr><tr><td class="patent-data-table-td ">41</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ørskov et al. "<a href='http://scholar.google.com/scholar?q="Biological+Effects+and+Metabolic+Rates+of+Glucagonlike+Peptide-1+7-36+Amide+and+glucagonlike+Peptide-1+7-37+in+Healthy+Subjects+Are+Indistinguishable"'>Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable</a>", Diabetes, 42:658-61 (1993).</td></tr><tr><td class="patent-data-table-td ">42</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Orskov et al. "<a href='http://scholar.google.com/scholar?q="Biological+Effects+and+Metabolic+Rates+of+Glucagonlike+Peptide-1+7-36+Amide+and+glucagonlike+Peptide-1+7-37+in+Healthy+Subjects+Are+Indistinguishable"'>Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable</a>", Diabetes, 42:658-61, 1993.</td></tr><tr><td class="patent-data-table-td ">43</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Orskov et al., "<a href='http://scholar.google.com/scholar?q="Is+the+Effect+of+Glucagon-like+Peptide-1+on+Gastric+Emptying+Centrally+Mediated%3F"'>Is the Effect of Glucagon-like Peptide-1 on Gastric Emptying Centrally Mediated?</a>", Diabetologia, Abstract A147, 38 Supp. 1:A39, (1995).</td></tr><tr><td class="patent-data-table-td ">44</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pelleymounter, et al, "<a href='http://scholar.google.com/scholar?q="Effects+of+the+obese+Gene+Product+on+Body+Weight+Regulation+in+ob%2Fob+Mice%2C"'>Effects of the obese Gene Product on Body Weight Regulation in ob/ob Mice,</a>" Science 269:540-543 (1995).</td></tr><tr><td class="patent-data-table-td ">45</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Raufman et al. "<a href='http://scholar.google.com/scholar?q="Exendin-3%2C+a+Novel+Peptide+from+Heloderma+horridum+Venom%2C+Interacts+with+Vasoactive+Intestinal+Peptide+Receptors+and+a+Newly+Described+Receptor+on+dispersed+Acini+from+Guinea+Pig+Pancreas%2C"'>Exendin-3, a Novel Peptide from Heloderma horridum Venom, Interacts with Vasoactive Intestinal Peptide Receptors and a Newly Described Receptor on dispersed Acini from Guinea Pig Pancreas,</a>" J. Biol. Chem. 266:2897-902 (1991).</td></tr><tr><td class="patent-data-table-td ">46</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Raufman et al. "<a href='http://scholar.google.com/scholar?q="Truncated+Glucagon-like+Peptide-1+Interacts+with+Exendin+Receptors+in+Dispersed+Acini+from+Guinea+Pig+Pancreas"'>Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas</a>", J. Biol. Chem. 267:21432-37 (1992).</td></tr><tr><td class="patent-data-table-td ">47</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Raufman et al. "<a href='http://scholar.google.com/scholar?q="Truncated+Glucagon-like+Peptide-1+Interacts+with+Exendin+Receptors+in+Dispersed+Acini+from+Guinea+Pig+Pancreas"'>Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas</a>", J. Biol. Chem. 267:21432-37, 1992.</td></tr><tr><td class="patent-data-table-td ">48</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ritzel et al., "<a href='http://scholar.google.com/scholar?q="GLP-1+%5B7-36+Amide%5D+Augments+Bisphasic+Insulin+Secretion+After+Intravenous+Glucose+in+Healthy+Volunteers%2C"'>GLP-1 [7-36 Amide] Augments Bisphasic Insulin Secretion After Intravenous Glucose in Healthy Volunteers,</a>" Diabetologia, Abstract A145, 38 Supp. 1:A39, (1995).</td></tr><tr><td class="patent-data-table-td ">49</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor 1989.</td></tr><tr><td class="patent-data-table-td ">50</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Scarpignato et al. "<a href='http://scholar.google.com/scholar?q="Action+of+Caerulein+on+gastric+emptying+of+the+Conscious+Rat"'>Action of Caerulein on gastric emptying of the Conscious Rat</a>", Arch. Int. Pharmacodyn. Ther. 246:286-94,1980.</td></tr><tr><td class="patent-data-table-td ">51</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Schepp et al. "<a href='http://scholar.google.com/scholar?q="Exendin-4+and+exendin-%289-39%29NH%26lt%3BSUB%26gt%3B2%26lt%3B%2FSUB%26gt%3B%3A+agonist+and+antagonist%2C+respectively%2C+at+the+rat+parietal+cell+receptor+for+glucagon-like+peptide-1-%287-36%29NH%26lt%3BSUB%26gt%3B2%26lt%3B%2FSUB%26gt%3B%2C"'>Exendin-4 and exendin-(9-39)NH&lt;SUB&gt;2&lt;/SUB&gt;: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH&lt;SUB&gt;2&lt;/SUB&gt;,</a>" Eur. J. Pharm. 269:183-91 (1994).</td></tr><tr><td class="patent-data-table-td ">52</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Schepp, et al. "<a href='http://scholar.google.com/scholar?q="Exendin-4+and+exendin-%289-39%29NH%26lt%3BSUB%26gt%3B2%26lt%3B%2FSUB%26gt%3B%3A+agonist+and+antagonist%2C+respectively%2C+at+the+rat+parietal+cell+receptor+for+glucagon-like+peptide-1-%287-36%29NH%26lt%3BSUB%26gt%3B2%26lt%3B%2FSUB%26gt%3B%2C"'>Exendin-4 and exendin-(9-39)NH&lt;SUB&gt;2&lt;/SUB&gt;: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH&lt;SUB&gt;2&lt;/SUB&gt;,</a>" Eur. J. Pharm. 269:183-91, 1994.</td></tr><tr><td class="patent-data-table-td ">53</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Schjoldager et al. "<a href='http://scholar.google.com/scholar?q="GLP-1+%28Glucagon-like+Peptide+1%29+and+Truncated+GLP-1%2C+Fragments+of+Human+Proglucagon%2C+Inhibit+Gastric+Acid+Secretion+in+Humans%2C"'>GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans,</a>" Dig Dis Sci 34 (5): 703-8 (1989).</td></tr><tr><td class="patent-data-table-td ">54</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Singh et al. "<a href='http://scholar.google.com/scholar?q="Use+of+%26lt%3BSUP%26gt%3B125%26lt%3B%2FSUP%26gt%3B1-%5BY%26lt%3BSUP%26gt%3B39%26lt%3B%2FSUP%26gt%3B%5Dexendin-4+to+characterize+exendin+receptors+on+dispersed+pancreatic+acini+and+gastric+chief+cells+from+guinea+pig%2C"'>Use of &lt;SUP&gt;125&lt;/SUP&gt;1-[Y&lt;SUP&gt;39&lt;/SUP&gt;]exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig,</a>" Regul. Pept. 53:47-59 (1994).</td></tr><tr><td class="patent-data-table-td ">55</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Singh et al. "<a href='http://scholar.google.com/scholar?q="Use+of+%26lt%3BSUP%26gt%3B125%26lt%3B%2FSUP%26gt%3BI-%5BY%26lt%3BSUP%26gt%3B39%26lt%3B%2FSUP%26gt%3B%5Dexendin-4+to+characterize+exendin+receptors+on+dispersed+pancreatic+acini+and+gastric+chief+cells+from+guinea+pig%2C"'>Use of &lt;SUP&gt;125&lt;/SUP&gt;I-[Y&lt;SUP&gt;39&lt;/SUP&gt;]exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig,</a>" Regul. Pept. 53:47-59 (1994).</td></tr><tr><td class="patent-data-table-td ">56</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Stower et al. "<a href='http://scholar.google.com/scholar?q="A+trial+of+glucagon+in+the+treatment+of+painful+biliary+tract+disease%2C"'>A trial of glucagon in the treatment of painful biliary tract disease,</a>" Br. J. Surg., 69:591-2, 1982.</td></tr><tr><td class="patent-data-table-td ">57</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Strandberg et al (Acta Radiologica, 1988, vol. 29, pp. 49-52).</td></tr><tr><td class="patent-data-table-td ">58</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Thorens et al. "<a href='http://scholar.google.com/scholar?q="Cloning+and+Functional+Expression+of+the+Human+Islet+GLP-1+Receptor%2C"'>Cloning and Functional Expression of the Human Islet GLP-1 Receptor,</a>" Diabetes 42 (11): 1678-82, 1993.</td></tr><tr><td class="patent-data-table-td ">59</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Thorens, "<a href='http://scholar.google.com/scholar?q="Expression+cloning+of+the+pancreatic+beta+cell+receptor+for+the+gluco-incretin+hormone+glucagon-like+peptide+1%2C"'>Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1,</a>" Proc. Natl. Acad. Sci. USA 89:8641-45, 1992.</td></tr><tr><td class="patent-data-table-td ">60</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Thorens, "<a href='http://scholar.google.com/scholar?q="Expression+cloning+of+the+pancreatic+cell+receptor+for+the+gluco-incretin+hormone+glucagon-like+peptide+1%2C"'>Expression cloning of the pancreatic cell receptor for the gluco-incretin hormone glucagon-like peptide 1,</a>" Proc. Natl. Acad. Sci. USA 89:8641-45 (1992).</td></tr><tr><td class="patent-data-table-td ">61</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Thorens, et al. "<a href='http://scholar.google.com/scholar?q="Cloning+and+Functional+Expression+of+the+Human+Islet+GLP-1+Receptor%2C"'>Cloning and Functional Expression of the Human Islet GLP-1 Receptor,</a>" Diabetes 42 (11): 1678-82 (1993).</td></tr><tr><td class="patent-data-table-td ">62</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Turton et al., Nature, vol. 379, pp. 69-72, 1996.</td></tr><tr><td class="patent-data-table-td ">63</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Turton, et al, "<a href='http://scholar.google.com/scholar?q="A+role+for+glucagon-like+peptide-1+in+the+central+regulation+of+feeding%2C"'>A role for glucagon-like peptide-1 in the central regulation of feeding,</a>" Nature 379:69-72 (1996).</td></tr><tr><td class="patent-data-table-td ">64</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Vandermeers et al, European Journal of Biochemistry, 1987, vol. 164, pp. 321-327.</td></tr><tr><td class="patent-data-table-td ">65</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Veale, P.R., et al, "<a href='http://scholar.google.com/scholar?q="The+presence+of+islet+amyloid+polypeptide%2Fcalcitonin+gen-related+peptide%2Fsalmon+calcitonin+binding+sites+in+the+rat+nucleus+accumbens%2C"'>The presence of islet amyloid polypeptide/calcitonin gen-related peptide/salmon calcitonin binding sites in the rat nucleus accumbens,</a>" European Journal of Pharmacology 262:133-141 (1994).</td></tr><tr><td class="patent-data-table-td ">66</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Wang et al. "<a href='http://scholar.google.com/scholar?q="Glucagon-like+Peptide-1+Is+a+Physiological+Incretin+in+Rat%2C"'>Glucagon-like Peptide-1 Is a Physiological Incretin in Rat,</a>" J. Clin. Invest., 95:417-21 (1995).</td></tr><tr><td class="patent-data-table-td ">67</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Wang, Y.J. and Hanson, M.A. "<a href='http://scholar.google.com/scholar?q="Parenteral+Formulations+of+Proteins+and+Peptides%3A+Stability+and+Stabilizers%2C"'>Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers,</a>" Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S, 1988.</td></tr><tr><td class="patent-data-table-td ">68</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Watson, N., et al, "<a href='http://scholar.google.com/scholar?q="Effects+of+captopril+on+glucose+tolerance+in+elderly+patients+with+congestive+cardiac+failure%2C"'>Effects of captopril on glucose tolerance in elderly patients with congestive cardiac failure,</a>" Current Medical Research and Opinion 12(6):374-378 (1991).</td></tr><tr><td class="patent-data-table-td ">69</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Wettergren et al. "<a href='http://scholar.google.com/scholar?q="Truncated+GLP-1+%28Proglucagon+78-107-Amide%29+Inhibits+Gastric+and+Pancreatic+Functions+in+Man%2C"'>Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man,</a>" Dig Dis Sci 38 (4): 665-73 (1993).</td></tr><tr><td class="patent-data-table-td ">70</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Willms et al. "<a href='http://scholar.google.com/scholar?q="Gastric+Emptying%2C+Glucose+Responses%2C+and+Insulin+Secretion+after+a+Liquid+Test+Mel%3A+Effects+of+Exogenous+Glucagon-Like+Peptide-1+%28GLP-1%29-%287-36%29+Amide+in+Type+2+%28Noninsulin-Dependent%29+Diabetic+Patients%2C"'>Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Mel: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients,</a>" J. Clin. Endocrinol. Metab. 81(1):327-32 (1996).</td></tr><tr><td class="patent-data-table-td ">71</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Young, et al, Program and Abstracts, 10&lt;SUP&gt;th &lt;/SUP&gt;International Congress of Endocrinology Jun. 12-15, 1996, San Francisco, p. 419 (P2-58).</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7521423">US7521423</a></td><td class="patent-data-table-td patent-date-value">Jul 20, 2004</td><td class="patent-data-table-td patent-date-value">Apr 21, 2009</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Exendin pharmaceutical compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8026210">US8026210</a></td><td class="patent-data-table-td patent-date-value">Jan 14, 2009</td><td class="patent-data-table-td patent-date-value">Sep 27, 2011</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Exendins and exendin agonist analogs to regulate gastrointestinal motility</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8080516">US8080516</a></td><td class="patent-data-table-td patent-date-value">Jun 29, 2005</td><td class="patent-data-table-td patent-date-value">Dec 20, 2011</td><td class="patent-data-table-td ">Conjuchem, Llc</td><td class="patent-data-table-td ">Long lasting synthetic exendin-4 peptide conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8084414">US8084414</a></td><td class="patent-data-table-td patent-date-value">Aug 30, 2005</td><td class="patent-data-table-td patent-date-value">Dec 27, 2011</td><td class="patent-data-table-td ">Conjuchem, Llc</td><td class="patent-data-table-td ">Methods involving long lasting synthetic exendin-4-peptide conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8093206">US8093206</a></td><td class="patent-data-table-td patent-date-value">Dec 14, 2005</td><td class="patent-data-table-td patent-date-value">Jan 10, 2012</td><td class="patent-data-table-td ">Conjuchem, Llc</td><td class="patent-data-table-td ">Methods involving long lasting synthetic exendin-4 peptide conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8299025">US8299025</a></td><td class="patent-data-table-td patent-date-value">Apr 22, 2008</td><td class="patent-data-table-td patent-date-value">Oct 30, 2012</td><td class="patent-data-table-td ">Intarcia Therapeutics, Inc.</td><td class="patent-data-table-td ">glucagon-like peptide-1; osmotic drug delivery device and method</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8575097">US8575097</a></td><td class="patent-data-table-td patent-date-value">Apr 23, 2010</td><td class="patent-data-table-td patent-date-value">Nov 5, 2013</td><td class="patent-data-table-td ">Pegbio Co., Ltd.</td><td class="patent-data-table-td ">Exendin variant and conjugate thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010121559A1?cl=en">WO2010121559A1</a></td><td class="patent-data-table-td patent-date-value">Apr 23, 2010</td><td class="patent-data-table-td patent-date-value">Oct 28, 2010</td><td class="patent-data-table-td ">Pegbio Co., Ltd.</td><td class="patent-data-table-td ">Novel exendin variant and conjugate thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011064316A2?cl=en">WO2011064316A2</a></td><td class="patent-data-table-td patent-date-value">Nov 25, 2010</td><td class="patent-data-table-td patent-date-value">Jun 3, 2011</td><td class="patent-data-table-td ">Paolo Botti</td><td class="patent-data-table-td ">Mucosal delivery of peptides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013090454A2?cl=en">WO2013090454A2</a></td><td class="patent-data-table-td patent-date-value">Dec 12, 2012</td><td class="patent-data-table-td patent-date-value">Jun 20, 2013</td><td class="patent-data-table-td ">Receptos, Inc.</td><td class="patent-data-table-td ">Novel glp-1 receptor modulators</td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc530/defs530.htm&usg=AFQjCNEOd3srpZKCSH0W93D5fiJ4_0S25w#C530S303000">530/303</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S278100">424/278.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc530/defs530.htm&usg=AFQjCNEOd3srpZKCSH0W93D5fiJ4_0S25w#C530S300000">530/300</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0035560000">A61K35/56</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0009000000">A61P9/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0003100000">A61P3/10</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0045000000">A61K45/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0003060000">A61P3/06</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038000000">A61K38/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0003040000">A61P3/04</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0005000000">C07K5/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038170000">A61K38/17</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038230000">A61K38/23</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0014620000">C07K14/62</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0014575000">C07K14/575</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038220000">A61K38/22</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K38/22">A61K38/22</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K38/00">A61K38/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=Y10S514/866">Y10S514/866</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K47/12">A61K47/12</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K47/10">A61K47/10</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K9/0019">A61K9/0019</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K38/2207">A61K38/2207</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K47/02">A61K47/02</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07K14/57563">C07K14/57563</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K47/44">A61K47/44</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K38/2264">A61K38/2264</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K47/26">A61K47/26</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=XXt_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K38/23">A61K38/23</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61K38/23</span>, <span class="nested-value">A61K47/44</span>, <span class="nested-value">A61K47/10</span>, <span class="nested-value">A61K9/00M5</span>, <span class="nested-value">A61K47/02</span>, <span class="nested-value">A61K47/26</span>, <span class="nested-value">A61K47/12</span>, <span class="nested-value">A61K38/22K</span>, <span class="nested-value">A61K38/22A</span>, <span class="nested-value">A61K38/22</span>, <span class="nested-value">C07K14/575L</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Oct 26, 2012</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ASTRAZENECA PHARMACEUTICALS LP, DELAWARE</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20120919</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">AMYLIN PHARMACEUTICALS, LLC ASSIGNS AN EQUAL AND UNDIVIDED ONE-HALF OF ITS ENTIRE RIGHT, TITLE AND INTEREST TO ASTRAZENECA PHARMACEUTICALS LP;ASSIGNOR:AMYLIN PHARMACEUTICALS, LLC;REEL/FRAME:029195/0555</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 25, 2012</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20120808</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">AMYLIN PHARMACEUTICALS, LLC, CALIFORNIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:AMYLIN PHARMACEUTICALS, INC.;REEL/FRAME:029198/0345</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 1, 2012</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">RELEASE BY SECURED PARTY;ASSIGNOR:ELI LILLY AND COMPANY;REEL/FRAME:029057/0342</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20120808</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">AMYLIN PHARMACEUTICALS, INC., CALIFORNIA</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 22, 2011</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">THE PATENTABILITY OF CLAIMS 18-20 IS CONFIRMED. CLAIMS 2, 7-9, 21, 23, 27-29, 34 AND 36 ARE CANCELLED. CLAIMS 1, 22 AND 25 ARE DETERMINED TO BE PATENTABLE AS AMENDED. CLAIMS 3-6, 10-17, 24, 26, 30-33, 35 AND 37, DEPENDENT ON AN AMENDED CLAIM, ARE DETERMINED TO BE PATENTABLE. NEW CLAIMS 38-40 ARE ADDED AND DETERMINED TO BE PATENTABLE.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 8, 2011</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20111107</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:AMYLIN PHARMACEUTICALS, INC.;REEL/FRAME:027192/0334</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ELI LILLY AND COMPANY, INDIANA</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Apr 22, 2011</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 4, 2011</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20100917</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 20, 2006</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">AMYLIN PHARMACEUTICALS, INC., CALIFORNIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BEELEY, NIGEL ROBERT ARNOLD;BHAVSAR, SUNIL;YOUNG, ANDREWA.;AND OTHERS;REEL/FRAME:017043/0824;SIGNING DATES FROM 20041001 TO 20041129</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 2, 2004</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">AMYLIN PHARMACEUTICALS, INC., CALIFORNIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BEELEY, NIGEL ROBERT ARNOLD;BHAVSAR, SUNIL;YOUNG, ANDREWA.;AND OTHERS;REEL/FRAME:015411/0905;SIGNING DATES FROM 20011129 TO 20041129</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U2Mwz1qGKCg1bYmVvKRdoxxLua9yA\u0026id=XXt_BAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U3SbZAd2QFoJJ-0a9DEAsxIv2-jgw\u0026id=XXt_BAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U0y8LST7mQQIlTQZl8aTvr4cChR2Q","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Pharmaceutical_compositions_containing_e.pdf?id=XXt_BAABERAJ\u0026output=pdf\u0026sig=ACfU3U04znDgnkI4k6WFakq_-0GqoNzJIA"},"sample_url":"http://www.google.com/patents/reader?id=XXt_BAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>